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 Streptococcus pneumoniae, or pneumococcus, remains the most prevalent cause 
of bacterial pneumonia worldwide. The burden of pneumococcal disease peaks among 
children and the elderly, while young adults are well protected against disease from all 
pneumococcal serotypes. Whether memory B cells play a role in this naturally 
developing serotype-independent immunity has not been determined. Additionally, lung 
resident memory B cells (BRM cells) are elicited after influenza infections of mice, but 
their relevance to bacterial pathogens and to humans remains unknown, as do the signals 
required for their establishment. We sought to address these knowledge gaps. 
We found that respiratory pneumococcal exposures in mice elicited lung BRM 
cells without concurrent tertiary lymphoid structure formation. Additionally, normal 
human lung tissue is enriched for B cells bearing a resident memory phenotype. Mice 
exposed to a low virulence pneumococcal strain were protected from a subsequent 
serotype-mismatched pneumococcal challenge. To address the role of B cells in this lung 
defense, we used a genetically engineered mouse strain allowing effective depletion of 
lung B cells bearing programmed death-ligand 2 (PD-L2, a memory B cell marker). 
When pneumococcus-experienced mice were depleted of PD-L2+ B cells just before the 
 
 ix
challenge infection, they experienced substantial defects in bacterial clearance compared 
to mice with lung B cells intact. These results provide the first evidence of a role for lung 
BRM cells in anti-bacterial immunity. Notably, this defense was pneumococcal serotype-
independent, distinguishing it from the serotype-specific immunity elicited by current 
pneumococcal vaccines. Finally, we found that the establishment of lung BRM cells in 
mice requires CD4+ T cells and multiple respiratory pneumococcal exposures. A second 
pneumococcal infection, but not the first, induces lung chemokine (C-X-C motif) ligand 
13 (CXCL13) production, establishment of local germinal center reactions, and 
accumulation of class-switched BRM cells in the lung.  
In conclusion, herein we show that lung BRM cells are a common feature of 
antigen-experienced lungs and describe the kinetics of lung BRM cell establishment and 
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CHAPTER ONE- INTRODUCTION 
Pneumonia 
The constant environmental exposure of our airways combined with the delicate 
anatomical structures required for respiration confer a particular susceptibility to disease 
and damage to the human lung. Indeed, lower respiratory tract infections (LRTIs) were 
the 4th leading cause of morbidity globally in 2017, and are the only type of 
communicable disease to remain a top 30 cause of morbidity in high socio-demographic 
index countries for the past three decades (1). Two of the largest disease outbreaks in the 
last century, the 1918 influenza pandemic and ongoing coronavirus disease-19 (COVID-
19) pandemic, were caused by respiratory pathogens, highlighting the devastating toll 
respiratory infections can take. Pneumonia, a type of LRTI, occurs when infection 
triggers immune cells and fluid to fill the alveoli, hindering the ability of the lung to carry 
out its primary function of exchanging gases between the airspaces and the blood. 
Pneumonia has been recognized as a common disease since the time of Hippocrates (2), 
especially among elderly individuals; a century ago, pneumonia was described in a 
medical textbook as “…the natural end of old people” (3). Despite the many advances of 
modern medicine, pneumonia remains extremely common, representing the leading cause 
of hospitalization among children (4) and most deadly cause of hospitalization among 





Figure 1. Pneumonia hospitalizations and deaths by age in the United States from 
2007-2009. Reprinted with permission from: Quinton and Mizgerd, Annu. Rev. Physiol. 
2015 (6). 
 
Perhaps one reason for the frequent occurrence of pneumonia is the wide variety of 
pathogens that can lead to the condition. These include diverse bacteria, viruses, and 
fungi (7). Novel microbial causes of pneumonia, such as the severe acute respiratory 
syndrome (SARS)-associated coronaviruses, continue to emerge. This complex and often 
poorly defined etiology represents a major difficulty we face in defending against 
pneumonia. 
Pneumococcal pneumonia 
Streptococcus pneumoniae was first isolated in 1881, and the long history of 




landmark importance, including Gram staining, bacterial transformation, and the acute 
phase response (8, 9). Pneumonia resulting from S. pneumoniae infection, referred to as 
pneumococcal pneumonia, is the most common bacterial etiology of community-acquired 
pneumonia (CAP), or pneumonia acquired during the normal activities of daily life 
outside of healthcare settings (10, 11). Infection with S. pneumoniae can lead to a variety 
of pathologies in addition to pneumonia, such as ear infection (otitis media), bacteremia, 
and meningitis (12). However, in the US, pneumococcal pneumonia is the leading cause 
of hospitalization due to pneumococcal infection and the most costly, accounting for 72% 
of medical costs related to pneumococcal disease (13). One of the most unique and 
challenging facets of S. pneumoniae is the large number of different serotypes known to 
exist, which recently increased to 100 (14). These serotypes are defined by different 
structural compositions of the polysaccharide capsule that encompasses the bacterial cell 
wall.   
The natural reservoir of S. pneumoniae is the human nasopharynx, and 
colonization of children is especially common, with essentially all children being 
colonized multiple times by the age of 2 (15). The incidence of pneumococcal 
colonization decreases with age, although it is not uncommon in adults, of whom 
approximately 10% are colonized at any given time (16). Nasal colonization is a pre-




Immunity to Streptococcus pneumoniae 
Innate mucosal responses 
Upon entering a new naive host, the pneumococcus faces some barriers to initial 
colonization, including the mucus layer and anti-microbial peptides such as lysozyme 
secreted by nasal epithelial cells (18). However, S. pneumoniae is well-adapted to these 
conditions (discussed below) and expresses many adhesion molecules that allow it to 
easily attach to the nasal epithelium and colonize the nose asymptomatically. Progression 
into the lung, where the interaction between pneumococcus and host becomes 
pathogenic, occurs via aspiration but is limited by the physical action of the mucociliary 
clearance mechanism and bacteria-aggregating effect of surfactant proteins (19). If 
pneumococci are able to bypass these barriers, they must also contend with the highly 
phagocytic alveolar macrophages of the lung, which are activated after detection of the 
bacteria via pattern recognition receptors. Clearance by alveolar macrophage-mediated 
phagocytosis is sufficient to prevent severe infection by bacteria that reach the alveoli in 
most cases of pneumococcal aspiration (20). However, when bacteria persist, 
macrophages and epithelial cells in the lung can secrete chemokines such as interleukin 
(IL)-8, chemokine (C-X-C motif) ligand 5 (CXCL5), and granulocyte-macrophage 
colony-stimulating factor (GM-CSF), which call in neutrophils from the circulation to aid 
in bacterial killing (20, 21). The accompanying extravasation of plasma into the lung can 
bring in additional immune mediators such as complement, acute phase proteins, or 
circulating antibodies (discussed below) (22). This inflammatory reaction to 




pneumococcal pneumonia, as the influx of fluid, immune cells and the cytotoxic products 
those immune cells produce can impair gas exchange and damage the host’s own tissues.   
Innate-like B cell responses to pneumococcus 
A less-appreciated aspect of innate immunity to pneumococcal pneumonia 
involves particular subsets of B cells. B lymphocytes are typically considered a 
component of the adaptive immune system. However, the B cell lineage can be more 
broadly divided into conventional follicular or “B2” B cells and two more innate-like 
subsets: “B1” B cells and marginal zone (MZ) B cells. B1 and MZ B cells also contribute 
to innate immune responses against S. pneumoniae.  
B1 B cells are a long-lived and self-replenishing subset that express an 
IgM+CD11b+B220loCD43+ surface marker phenotype when not activated (23). Most, 
but not all, B1 cells also express the inhibitory receptor CD5, which may be important for 
preventing autoimmune reactions by these frequently self-reactive cells (24). B1 cells 
develop largely in fetal tissues, are derived from B1-specific progenitors (25), and have a 
distinct anatomical localization compared to B2 or MZ B cells; although some are found 
in lymphoid tissues, many mature B1 cells migrate to the peritoneal and pleural cavities 
in response to macrophage-secreted CXCL13 and comprise the majority of B cells at 
these sites in mice (26). 
In mice, B1 cells are capable of performing multiple effector functions important 
in responses to bacterial pathogens such as S. pneumoniae. Some B1 cells in the spleen 
and bone marrow constitutively secrete natural antibodies, which are made in the absence 




Natural antibodies are primarily of the IgM isotype and are well-suited for activation of 
the classical complement pathway to eliminate bound targets (23). These targets are 
usually evolutionarily conserved antigens such as phosphorylcholine (PCho), which is a 
unique part of the pneumococcal cell wall. Natural anti-PCho antibodies constitutively 
produced by CD5+ B1 cells provide a first line of defense against pneumococcal invasion 
of the blood (28, 29). In contrast, CD5- B1 cells in the mouse peritoneum can respond in 
an antigen-specific manner to pneumococcal infection and produce protective capsular 
polysaccharide-specific IgM and IgG3 antibodies (29).  
The existence of analogous B1 cells in humans has been controversial due to the 
lack of definitive distinguishing surface markers (30, 31). However, there is a clear role 
in bacterial immunity for human B1-like cells (CD19+CD20+CD43+CD27+CD70-) (32), 
which, along with traditional plasma cells, produce IgM, IgG, and IgA antibody against 
pneumococcal polysaccharide (33, 34).  
 MZ B cells (IgMhiIgDloCD21hiCD23-) develop from the same precursor cells as 
follicular B2 cells (25) and are named based on their enrichment in the splenic marginal 
zone surrounding the B cell follicles (35). At this site, MZ B cells are poised to respond 
to blood-borne antigens. Like B1 cells, MZ B cells respond to the pneumococcal 
polysaccharide in a T cell-independent manner to rapidly generate large amounts of 
serotype-specific IgM and some class-switched antibodies (35, 36). Although the 
pneumococcal polysaccharide-specific responses of B1 and MZ B cells are not 
technically innate, as they involve antigen-specific antibodies produced during infection, 




in defending against the potentially deadly invasion of pneumococci into the blood while 
a typical adaptive immune response develops.    
Pneumococcal innate immune evasion 
Although the above sections make clear that the immune system has many tools 
in its innate arsenal to prevent pneumococcal infection, S. pneumoniae also has a wide 
array of virulence factors that enable it to avoid these immune defenses. The most notable 
means of evading the immune system by S. pneumoniae is definitively the polysaccharide 
capsule. The negative charge of most pneumococcal capsules electrostatically prevents 
entrapment of the bacteria by mucus, which is also negatively charged (37). The steric 
hindrance of the capsule prevents efficient binding of complement, acute phase proteins, 
and antibody specific to internal bacterial structures (38). Even when such immune 
effectors manage to bind the bacteria, the capsule allows evasion of efficient 
opsonophagocytosis mechanisms by sterically hindering their interactions with 
corresponding receptors on phagocytes (38). In addition to capsule, bacterial enzymes are 
another main class of pneumococcal virulence factors enabling innate immune invasion. 
The enzymes PdgA and Adr, for example, modify the cell wall to confer resistance to 
degradation by mucosal antimicrobial peptides (39). The bacterial enzymatic toxin 
pneumolysin, along with other enzymes, causes epithelial cell damage and prevents 
effective mucociliary clearance (40). Pneumolysin can also lead to cell death of 
phagocytes, impairing efficient host bacterial clearance (41). Still other enzymes, 
pneumococcal surface endonucleases, enable bacterial escape from neutrophil 




contains one or more evasive mechanisms, highlighting the importance of the more 
potent, if slower, adaptive immune response. 
Vaccine-elicited adaptive immunity to pneumococcus 
In the 1918 flu pandemic, secondary bacterial pneumonia caused many of the 
millions of deaths worldwide (43), leading to recognition of the potential benefits of 
intentionally tipping the balance of the host-pathogen arms race to favor the immune 
response against pneumococcus. Multiple attempts to immunize with inactivated 
pneumococci were carried out during the 1918 pandemic, with varying efficacy (44). In 
1945, the power of immunization with individual pneumococcal capsular polysaccharides 
for generating serotype-specific (homotypic) immunity was realized (45), leading to the 
eventual 1977 approval of a first pneumococcal polysaccharide-based vaccine (46).  
 The adaptive immune response to these polysaccharide vaccines is T cell-
independent, because the repeating polysaccharide epitopes are able to cross-link the B 
cell receptor (BCR) and activate B cells in the absence of T cell help (47). However, 
because T cells generally respond only to protein antigens, these vaccines cannot 
generate the T cell help required for high affinity antibody production and memory B cell 
(MBC) responses (48). While polysaccharide vaccine-elicited plasma cells and resulting 
antibodies still provide protection against invasive pneumococcal disease in most adults 
(49, 50), children under 2 years old do not generate robust anti-polysaccharide immune 
responses (51). To provide protection against pneumococcal disease in this vulnerable 
population, a new vaccine approach where each polysaccharide capsule is conjugated to a 




more effective in providing protection in young children and immunocompromised 
individuals due to their ability to elicit carrier protein-specific T cell help that promotes 
high affinity plasma cell responses and B cell memory (46, 48).  
Today, a polysaccharide vaccine including the capsules of 23 pneumococcal 
serotypes and a conjugate vaccine including the capsules of 13 serotypes are used in the 
US (46). Interestingly, although these vaccines provide good protection against invasive 
diseases (bacteremia, meningitis, and pleural infection) caused by the included serotypes, 
neither type has high efficacy in preventing pneumococcal pneumonia (52). Other 
limitations of these vaccines include the technical difficulty in including more serotypes 
and the observation of serotype replacement, where disease caused by serotypes not 
included in the vaccines increased in prevalence as protection against vaccine serotypes 
became widespread (53, 54). Both the currently licensed vaccines are predicated on 
eliciting antibodies targeting the serotype-defining pneumococcal capsule, which have 
been known to provide serotype-specific protection since the successful use of passive 
anti-pneumococcal serum transfer early in the 20th century (55). The idea of serotype-
specific immunity as the driving force of anti-pneumococcal protection has been so 
prevalent that the immunologist Charles Janeway Jr. wrote that, “from the point of view 
of the adaptive immune system, each serotype of S. pneumoniae represents a distinct 
organism” (56). Certainly, for the adaptive immunity elicited by current pneumococcal 




Naturally acquired adaptive immunity to pneumococcus 
In contrast to vaccine-derived immunity, naturally acquired immunity refers to the 
immune responses that develop from natural exposures to a pathogen. Initially, naturally 
acquired protection against pneumococcal disease was also believed to largely derive 
from the development of serotype-specific antibodies following childhood colonization 
events (57-59). Indeed, pneumococcal colonization often results in systemic capsule-
specific antibodies (16, 60). More recent studies have directly explored the contributions 
of colonization-elicited antibodies and other immune system components to protection 
against subsequent serotype-matched (homotypic) pneumococcal colonization or 
pneumonia in mice (Table 1). Generally, prior pneumococcal colonization elicits 
immunity to subsequent homotypic colonization that is dependent on CD4+ T cells and 
not antibodies. Protection against homotypic pneumonia, on the other hand, requires pre-
existing antibodies and the long-lived plasma cells (LLPCs) that secrete them. 
Table 1. Observed contributions of various immune components to homotypic 










Not sufficient (61) 




CD4+ T Cells Required (66) 
Not required (62, 63) 
Required (64) 
Memory B Cells  Not required (62) 




Although serotype-specific protection is commonly observed in humans and mice, 
epidemiological evidence indicates that naturally acquired immunity against 
pneumococcal colonization and disease may actually rely on serotype-independent 
(heterotypic) mechanisms (67). Pneumococcal disease incidence decreases in adults for 
all serotypes, regardless of how commonly a serotype colonizes children, indicating that 
anti-capsule antibodies are not the primary mechanism of natural immunity (58). This 
idea was supported by experiments in mice showing that prior colonization by a 
pneumococcal serotype protected equally well against subsequent homotypic and 
heterotypic colonization (68). Whether prior colonization protects against a future 
heterotypic pneumonia episode in mice has been less obvious. Two studies report no such 
protection (Table 2), and some authors have argued that pneumococcal exposures within 
the lung itself are required to provide definitive heterotypic protection against subsequent 
pneumonia (65). This idea is at odds with the fact that only a small minority of children 
exposed to pneumococcus experience a true pneumonia episode, while protection against 
pneumonia in young adults is common (67). The epidemiology therefore better aligns 
with three other studies in mice that did report colonization-elicited heterotypic 
protection against pneumococcal pneumonia (Table 2). Additionally, studies in humans 
have shown colonization-induced changes to lung immune components in the 
bronchoalveolar lavage fluid (BALF) (69, 70). Altogether, the epidemiologic and 
experimental evidence indicates that heterotypic naturally acquired protection against 
pneumococcal colonization and pneumonia in adults is elicited by the colonization events 









strain D39 (71) 
No 
Colonization with 
strain TIGR4 (62) 
Yes 





Colonization with a 




strain Sp23F (65) 
No 
Direct lung infection 
with strain Sp23F (65) 
Yes 
Direct lung infection 
with strain Sp19F (74) 
Yes 
Table 2. Studies showing a presence or absence of heterotypic protection against 
pneumococcal pneumonia after prior colonization or direct lung infection. 
 
Many groups have investigated the immunological mechanisms behind this 
heterotypic naturally acquired protection. Table 3 describes the observed contributions of 
various immune components to protection conferred by prior exposure to live 






Table 3. Observed contributions of various immune components to heterotypic 
protection against secondary pneumococcal colonization or pneumonia in mice. 
1These authors observed an association between serum antibodies against pneumococcal 
proteins and lower incidence of respiratory tract infections (but not pneumococcal 
colonization)in children. 2These authors transferred pooled human serum 
immunoglobulin depleted of antibody against pneumococcal capsules into mice, which 
protected mice against pneumococcal lung infection.  
 
There is strong evidence that CD4+ T cells generated by pneumococcal exposures 
are required for protection against subsequent heterotypic colonization and pneumonia. 
Most of these studies further show that it is specifically IL-17-producing CD4+ T cells 
that are important for this protection (65, 74-76). Most evidence indicates that serotype 
cross-reactive antibodies are dispensable for heterotypic protection against pneumococcal 
colonization in mice and are not associated with such protection in humans. However, 
these antibodies do appear to be important in both mice and humans for protection 
against heterotypic pneumococcal lung infection.  
 Altogether, the studies summarized above indicate a mechanism of naturally 
acquired immunity to pneumococcus that requires IL-17-producing CD4+ T cells for 





















No association with 







protection against pneumonia. Serotype cross-reactive antibodies, on the other hand, 
appear to be dispensable for immunity to colonization but crucial for protection within 
the lung itself. Despite the proven importance of antibodies in this setting, nearly all 
studies have focused only on heterotypic protection conferred by pre-existing serum 
antibodies. Other potentially important sources of antibody, such as pre-existing 
antibodies in the lung airspaces or reactivated MBCs, have not been investigated in the 
context of natural heterotypic immunity to pneumococcal pneumonia.  
Memory B Cells 
 Pathogens such as Streptococcus pneumoniae reproduce on time scales that are 
orders of magnitude greater than humans do and therefore can evolve over the course of 
hours to days vs. decades and centuries. The adaptive immune system is what allows the 
human species to compete with the multitude of rapidly changing pathogens around us. 
Typical B and T lymphocytes are set apart from the cells of the innate immune system in 
that each cell bears receptors that are highly specific for a single (usually) non-self 
antigen. These receptors are generated by a random recombination process of the 
adaptive receptor genetic loci. This process enables the production of lymphocytes with 
at least 1011 different potential specificities (56), such that the adaptive immune cell 
repertoire can essentially recognize any possible antigen, even those that don’t exist 
naturally. The fundamental trade-off that accompanies this vast diversity in specificity is 
that T or B cells that recognize a given epitope are extremely rare in a naïve host. This 
problem is addressed by the concentration of lymphocytes in specialized secondary 




invading pathogen, as well as the huge proliferative capacity of lymphocytes once 
activated. The requirement for these initial recognition and proliferation steps in a 
primary adaptive immune response is why the response develops more slowly than an 
innate immune response, over weeks instead of hours to days. But evolution has also 
provided adaptive immunity with a key tool in the fight against frequently encountered 
pathogens: immunologic memory.  
Memory T and B lymphocytes represent a small fraction of the cells initially 
activated in a primary response and remain in the host long after the infection is resolved. 
Memory cells specific to a pathogen are present at a higher frequency than the 
corresponding naïve cells were during the initial infection, and memory lymphocytes, 
although quiescent most of the time, are poised to carry out effector functions upon 
activation faster than naïve cells do. These factors enable secondary responses to a 
previously seen pathogen to occur much more rapidly than the primary response did. 
After recovery from some infections, the resulting immunologic memory is able to persist 
for the rest of a human lifetime. The power and longevity of immunological memory was 
recorded in 1846, when the measles virus had infected over 75% of residents on the Faroe 
islands. The last known occurrence of measles in this isolated part of the world had been 
in 1781, and none of the elderly residents in 1846 who were infected 65 years earlier 
became ill a second time due to their immunologic memory (81). 
The generation of B cell memory 
In a typical T cell-dependent primary immune response, B cells are usually 




macrophages in the subcapsular sinus or follicular dendritic cells (FDCs) in the center of 
the B cell follicle (82). Either mode of recognition triggers BCR clustering, which results 
in signaling through the BCR (83) and changes to the B cell cytoskeleton allowing 
clathrin-mediated engulfment of the BCR and bound antigen (84). Like T cells, B cells do 
not achieve full activation upon BCR engagement alone, except in the case of highly 
multivalent antigens like the pneumococcal polysaccharide. A second signal can come in 
the form of toll-like receptor (TLR) signaling, which directs antigen-stimulated B cells to 
differentiate directly into plasma cells (85). Otherwise, the second signal is derived from 
helper T cells. After engulfing BCR-bound antigen, and in the absence of TLR 
engagement, the B cell can process and present peptides on MHC class II at its surface. 
BCR signaling in response to T cell-dependent antigens also enables B cells to move to 
the interface of the follicle and T cell zone (“the T-B border”) (84). This relocation and 
presentation of antigen allows for the first contact-dependent B cell:T cell interaction of 
the immune response: recognition of the peptide-bearing B cell by helper T cells of the 
same pathogen specificity that were previously activated by an antigen-presenting cell 
(APC). Recognition allows the T cell to provide help to the B cell in the form of surface 
co-stimulatory molecules (particularly CD40L) as well as cytokines (particularly IL-21 
and IL-4), which then instruct the B cell to continue to proliferate and differentiate (86). 
It is also at this stage that the majority of isotype switching of the BCR constant region is 
initiated and completed based on cues from cytokines and T cell help (87). This initial T 
cell:B cell interaction drives differentiation of some B cells to become early 




but are generally short-lived (88). Other of the B cells become extrafollicular MBCs, 
which are typically IgM+ but can express IgG or IgA BCRs (89). Finally a third group of 
B cells instead upregulate the transcription factor Bcl-6, migrate, and form a germinal 
center (GC) reaction within the follicle where they have the opportunity to mature their 
BCRs to better bind the relevant antigens (90). BCR affinity (and the proportional length 
of time that T cell help is received) plays a role in determining which of these three fates 
an individual naïve B cell follows. Cells with higher affinity BCRs are predisposed to 
become plasma cells, while lower affinity cells tend to differentiate into extrafollicular 
MBCs, and cells with intermediate affinity favor GC entry (91). This division of labor is 
efficient in that it leads to early production of relatively low affinity antibodies and 
memory cells as well as slower development of antibodies and cells with better 
specificity to the invading pathogen. 
Within the GC, a cyclical microevolutionary process occurs, involving repeated 
rounds of mutation and selection. FDCs act as professional retainers of antigen within the 
GC, allowing ongoing antigen-driven selection. Newly arrived GC B cells bind this 
antigen on FDCs and present it to cognate TFH cells within the GC “light zone”; TFH 
cells provide help and instruct certain of the GC B cells to migrate into the GC “dark 
zone”, mutate their BCR, and proliferate (90). This somatic mutation process relies on 
high expression of the enzyme Activation-induced cytidine deaminase (AID), which 
catalyzes the deamination of cytosine bases within the BCR locus, followed by low 
fidelity DNA repair mechanisms (92). A minority of these mutation events result in 




of GC TFH cells providing survival signals to the GC B cells acts as a selective force; 
GC B cells that mutated to express better affinity BCRs are able to have more frequent, 
prolonged, and stronger TFH interactions and thus preferentially receive positive 
selection in the form of T cell help (93, 94).  
B cells exiting the GC go on to become plasma cells or GC-derived MBCs (86). 
Again, this fate decision appears to be influenced by BCR affinity and duration of B 
cell:TFH contact, with higher affinity favoring IRF-4 and Blimp-1 transcription factor 
upregulation and the plasma cell fate (88, 93). This affinity-based selection is likely 
based on a combination of stronger signals through higher affinity BCRs and the fact that 
higher affinity B cells acquire and process antigen from FDCs more efficiently (94, 95). 
In accordance with this, MBCs appear to emerge first from the GC reaction, having 
accumulated fewer somatic mutations than cells fated to become LLPCs (Fig. 2). 
Although high expression of the transcription factor Bach2 is required for GC B cells to 





Figure 2. Sequential waves of B cell memory emerge during a primary immune 
response. Made using Biorender.com based on a figure in Weisel and Shlomchik, Annu. 
Rev. Immunol. 2017 (97). 
MBC markers and subsets 
Many initial studies of MBCs assumed these cells express only class-switched 
receptor isotypes (IgM-IgD-) (98). However, IgM+ MBCs have been definitively 
observed in humans and mice (99, 100). This, combined with the fact that isolation 
techniques involving the BCR can lead to undesirable B cell activation, necessitated the 
discovery of more nuanced marker combinations for practical MBC studies. Unlike many 
immunological principles that are characterized first in animal models, much of the initial 
knowledge regarding MBC markers was attained from human studies. This was in part 
due to the discovery in the 1990s of CD27 as a reliable surface marker of human MBCs 




These cells are CD27-, lack the usual expression of complement receptor 2 (CD21), and 
may be enriched for anergic or autoreactive cells (103-105). However, CD27 expression 
remains a reliable indicator of human MBCs. In mice, CD27 expression is not restricted 
to MBCs, necessitating use of either functional assays or an IgD-CD38+ surface marker 
phenotype to define these cells. The latter approach is unsatisfying, as murine naïve B 
cells also express high levels of CD38 (106). These challenges motivated a series of 
studies to define better mouse MBC markers; PD-L2, CD80, and CD73 were identified as 
three such surface markers that are expressed on memory, but not naïve, mouse B cells 
(107, 108). As shown in Table 4, MBCs expressing multiple of these markers are 
enriched for class-switched BCRs and have a higher BCR mutational load than MBCs 
not expressing them (109). While CD73 expression on MBCs did not seem to correlate 
with these phenotypes in initial studies, MBCs co-expressing CD73 with CD80 comprise 
an important subset of MBCs with mutated BCRs in various infection settings (110-112).  
 
Table 4. Characteristics of mouse MBC subsets as defined by expression of PD-L2, 






Relative Extent of 
BCR Mutation
Triple Low Low Lower










Transcriptionally, memory and naïve B lymphocytes are very similar (113, 114). 
However, there are key differences in MBCs that confer the typical advantages of a 
memory response: faster and stronger activation. For example, cell-cycle regulatory 
genes are down-regulated in MBCs compared to naïve B cells, such that MBCs can enter 
cell division quickly upon stimulation (115). MBCs also have higher expression of anti-
apoptotic molecules like Bcl-2, as well as proteins involved in homeostatic proliferation, 
like leukemia inhibitory factor receptor (113, 114). Unlike naïve B cells, MBCs 
constitutively express T cell co-stimulatory molecules (CD80/86), enabling them to 
quickly elicit T cell help (113, 116). Finally, changes to the intracellular signaling 
domains of class-switched BCRs confer IgG MBCs with enhanced sensitivity to low 
doses of antigen compared to B cells expressing IgM/IgD (117). This combination of 
subtle yet powerful changes allows MBCs to reactivate quickly and intensely to 
secondary challenge. 
The splenic MZ and the lymph node subcapsular sinuses are well-established 
niches for MBCs in mice and humans, although they are not the only sites of MBC 
localization (discussed in the next section) (118, 119). These sites are enriched with 
CD169+ macrophages as well as follicular memory T cells, enabling easy presentation of 
antigen to and reactivation of MBCs upon reinfection (118). In these specialized sites, 
MBC reactivation leads these cells to two main fates; proliferation and differentiation 
into plasma cells or entry into a secondary GC where the BCR is further matured and 




reactivated MBC have not been fully elucidated, but certain surface markers have been 
shown to associate with each outcome in murine MBCs. MBCs concurrently expressing 
PD-L2 and CD80 differentiate into plasma cells upon restimulation and do not seed 
secondary GCs. MBCs expressing neither of these markers instead form secondary GC 
responses, while MBCs expressing either CD80 or PD-L2 alone have an intermediate 
response phenotype (120). Interestingly, while secondary GC formation has been readily 
observed in murine experimental systems involving adoptive transfer and reactivation of 
MBCs, recent work indicates that this outcome is relatively rare for MBCs responding to 
challenge in an immunized mouse (121).  
The factors required for MBC reactivation are still an active area of research. 
Cognate antigen appears necessary for MBC reactivation in vivo (122). Once established, 
MBCs can survive independently of T cells, (123) but whether or not MBC reactivation 
is dependent on T cell help seems to be context-dependent. MBC responses to model 
antigens, such as hen egg lysozyme (118) and 4-hydroxy-3-nitrophenylacetyl (NP) (120), 
appear to require T cell help, but T cell-independent reactivation of MBCs specific to 
numerous viruses has been observed (124, 125). This T cell-independent activation 
required SLOs with unaltered lymphoid architecture (125). In contrast, activation of 
virus-specific MBCs in another study was T cell-dependent but could occur 
independently of SLOs (126). Therefore, it may be a combination of antigen structure 
and immune niche that dictate whether MBCs require T cell help to become plasma cells 





The roles of transcription factors and cytokines in MBC reactivation are only just 
beginning to be described. IL-2 and IL-15 appear to not be involved (127), but a recent 
study implicated IL-9 as a necessary signal for NP-specific MBC differentiation into 
plasma cells (128). Development, maintenance, and reactivation of IgG2a/c+ MBCs is 
dependent on the transcription factor T-bet, and MBCs of these isotypes are responsive to 
interferon-gamma signaling (129). In contrast, IgA+ MBC development and function 
requires the transcription factor RORα, and these MBCs are responsive to IL-17 and IL-
22 (129). Similar transcription factor and cytokine requirements specific to other MBC 
isotypes have yet to be defined. 
Tissue Resident Memory B Cells 
Following infection resolution, immunology dogma indicates that the long-lived 
memory feature of adaptive immunity is conferred by memory T and B lymphocytes and 
LLPCs in the spleen, lymph nodes, bone marrow, mucosa-associated lymphoid tissue 
(MALT), and blood. In recent decades, however, these concepts of immune cell 
localization have expanded beyond the classic lymphoid organs; many non-lymphoid 
tissues are now recognized to have profound roles in adaptive immunity as well. One of 
the largest paradigm shifts in adaptive immune cell localization was the discovery of 
tissue resident memory T cells (TRM cells), which populate non-lymphoid tissues that 
have recovered from infection or inflammation (130). TRM cells bear an effector 
memory phenotype but do not recirculate through the blood and lymph like effector 
memory T cells do (131). Although TRM cells were initially observed in non-lymphoid 




(132). Since their discovery, both CD4+ and CD8+ TRM cells have been described in 
multiple antigen-experienced tissues, infection settings, and species (133). TRM cells 
have even been well characterized in difficult-to-study human organs like the lung, where 
CD8+ TRM cells have been associated with better functional outcomes in viral infections 
(134, 135). While TRM cell studies have progressed at a rapid pace, research on 
analogous resident memory B cells (BRM cells) has a much shorter history. This 
discrepancy is likely due to the relative rarity of B cells within tissues compared to T 
cells (136) and the fact that one of the main B cell functions, antibody secretion, can be 
effective over a distance, making the benefits of a BRM cell population unclear.  
Lymphoid tissue BRM cells  
MBCs that do not re-enter the circulation have now been observed in several 
lymphoid tissues. As with T cells (137), there are MBCs that remain resident within 
draining lymph nodes (138, 139). BRM cells are also found in the bone marrow (140), 
and high T-bet expression was recently found to mark human and mouse MBCs that are 
preferentially retained as resident cells in the spleen and do not recirculate in the blood or 
lymphatics like T-bet-/T-betlo MBCs do (141). Oral immunization generates MBCs 
(primarily with IgA+ BCRs) localized within the Peyers’ patches of the gut (142). Intra-
tonsillar toxin immunizations elicit MBCs in human tonsils that preferentially localize to 
the tonsil that received the immunization, implying they may be resident there (143). 
RSV-specific MBCs with an atypical phenotype are found in the adenoids of human 
children; these MBCs produce antibodies with better virus neutralizing ability than 




compartment, though this was not formally tested (144). Although resident memory 
lymphocytes are typically considered in the context of non-lymphoid tissues, there are 
clearly many non-circulating MBCs that populate the immune tissues of the body where 
they may be poised for optimal reactivation and sentinel function. 
Lung BRM cells 
In contrast to the wide variety of non-lymphoid tissues and settings where TRM 
cells have been described, BRM cells have been observed rarely in healthy non-lymphoid 
tissues. Singular studies detected non-circulating MBCs in healthy human skin (145) and 
adipose tissue of mice (146). The majority of tissue BRM cell studies, however, have 
been in the context of the lung. 
In 1987, Jones and Ada provided initial hints that influenza infection in mice may 
establish MBCs in the lung by showing a stimulation-dependent increase in antibody-
secreting cells (ASCs) in influenza recovered lung cell suspensions (147). These authors 
further showed that the IgG, IgA, and IgM ASC precursors from these lungs were 
retained for 6 months post-infection, at which point they began to decline. Although this 
study was a pioneering effort in the field of immune memory localization and preceded 
the first descriptions of resident memory, the possible importance of these results was 
seemingly overlooked, and follow-up studies did not occur for over two decades. In 2008, 
the distribution of IgG and IgA MBCs to different sites in mice recovered from influenza 
pneumonia was characterized using modern variations on the technique implemented by 
Jones and Ada (148). Influenza-specific IgG and IgA MBCs were most frequent in the 




(NALT), and the lung. The lung MBC numbers were maintained for at least 12 weeks 
post-infection, leading these authors to revitalize the notion that the lung is a site of MBC 
accumulation and retention after influenza infection, although retention was not formally 
tested. In 2012, these observations were extended by the work of Onodera et al (112). 
Novel phenotypic findings of this study included that many of the virus-specific lung 
MBCs express the markers CD73, PD-L2, and CD80, which are associated with MBCs 
poised for antibody secretion on reactivation (120), as well as the marker CD69, which is 
expressed on many TRM cells. Importantly, this study also provided the first evidence of 
a functional role for lung MBCs; lung influenza-specific MBCs confer better protection 
against influenza challenge when transferred to a naïve mouse than spleen influenza-
specific MBCs do. Transfer of lung MBCs also correlated with higher virus-neutralizing 
antibody titers in the BALF after recipient challenge compared with spleen MBC 
transfer. These results indicated that the lung MBCs generated by flu infections in mice 
play an important part in respiratory anti-viral immunity and may be resident cells, 
although circulatory dynamics were not assessed.  Adachi et al. (149) then showed that 
the influenza-specific lung MBCs in mice were protected from an intravascular B cell 
antibody stain, providing the first evidence these cells were in the lung tissue and not the 
vasculature. After these groups confirmed that influenza infections definitively elicit lung 
MBCs in mice, a 2018 study showed that this observation may extend to human lungs as 
well; healthy lungs of 3 human donors were enriched for total and influenza-specific 
MBCs compared to unmatched human blood samples (150). However, none of the above 




the circulation. Definitive proof that lung MBCs generated by influenza infections of 
mice are resident and do not recirculate was provided in 2019 (139). These authors 
showed that if a mouse recovered from influenza was connected surgically via the 
circulatory system to a congenic partner mouse, the lung MBCs did not ever move into 
the partner mouse, indicating they did not enter the circulation at any point. This 
remained true regardless of whether the partner mouse was naïve, had recovered from 
influenza infection, or had ongoing LPS-induced lung inflammation. 
The phenomenon of B cell memory residing within lungs recovered from 
influenza infections has now been well-documented and extensively reviewed (151, 152). 
However, the exact location of these MBCs within the lung tissue has surprisingly not 
been addressed. A consistent feature of influenza infections in mice is that they elicit 
inducible bronchus-associated lymphoid tissue (iBALT), a lung tertiary lymphoid 
structure typically defined to include B and T cell areas in close proximity, ongoing GC 
reactions, and high endothelial venules (HEVs) (153). These structures can be observed 
in mouse lungs recovered from influenza for as long as a month after infection resolution, 
and are capable of retaining MBCs (149, 154). Disruption of influenza-induced iBALT in 
mice impaired secondary antibody responses to a challenge infection, leading to 
speculation that iBALT is a likely site of localization for lung BRM cells (155, 156). In 
support of this idea, transfer of influenza-specific lung MBCs only provided protection in 
naïve recipients if iBALT was pre-formed in the recipient lungs prior to transfer (112). 




infection observed large clusters of B and T cells with ongoing GC reactions, although 
the cells within the iBALT were not nearly as organized as is observed in SLOs (149). 
Therefore, at least some of the lung BRM cells generated after influenza appear to 
localize to iBALT structures. However, iBALT is not typically seen in the lungs of 
healthy humans, nor is it elicited by all respiratory infections (157). Pneumococcal 
infections of mice, for example, do not lead to iBALT structures detectable on 
hematoxylin and eosin (H & E) staining (74). This leads to the question of whether lung 
BRM cells are a feature unique to influenza infections or can be found in iBALT-free 
lungs that have been exposed to other, non-viral pathogens. Whether and how the kinetics 
of and signals for BRM cell establishment in the lungs would differ between influenza 
and other infection settings is also unclear.   
Research Objectives 
 The research described in this dissertation aims to address three main areas of 
investigation described in the above introduction that have not yet been elucidated by the 
scientific community. These are: 1) the contribution of MBCs to naturally acquired 
serotype-independent pneumococcal immunity; 2) the extent to which lung BRM cells 
are formed by bacterial respiratory infections and are maintained in iBALT-free lungs; 
and 3) the kinetics and signals required during BRM cell establishment outside the setting 





CHAPTER TWO: MATERIALS AND METHODS 
Mouse Strains 
All animal protocols were approved by the Boston University Institutional Animal 
Care and Use Committee. C57BL/6J mice were purchased from Jackson Laboratories 
(Bar Harbor, Maine). Ighmtm1cgn (µMT) B cell-deficient mice (158) on a C57BL/6 
background were purchased from Jackson Laboratories and maintained by breeding 
homozygous animals. Homozygous PZTD (PD-L2+ indicator knock-in and inducible 
knockout) mice with CD19-Cre transgenes were previously described (159). Mouse 
experiments were initiated when mice were 6-12 weeks of age and included both male 
and female animals. Mice were maintained in specific pathogen-free conditions on a 12 h 
light-dark cycle with ad libitum access to food and water.   
Bacterial Infections 
Anti-pneumococcal immunity was generated as previously described (74) by 
giving mice two exposures to S. pneumoniae serotype 19F (Sp19F EF3030, kindly 
provided by Dr. Marc Lipsitch) one week apart before allowing mice to recover for at 
least four weeks. Sp19F exposures were given either intratracheally (i.t.) or intranasally 
(i.n., only for Fig. 5I).  Mice were anesthetized via i.p. injection of ketamine (75 mg/kg 
for i.t. or 50 mg/kg for i.n.) and xylazine (5 mg/kg). For i.t. exposures, a small incision 
was made to expose the trachea, and a 24-gauge catheter (Becton Dickinson 381112) was 
inserted into the trachea and down into the left bronchus. A 50 µL volume containing 1  x 
106 bacterial CFU was instilled in the left lung lobe of each mouse. For i.n. exposures, 50 




instilled into each mouse until it was inhaled completely. Challenge infections after the 
development of immunity were given by i.t. instillation of 0.5-1 x 106 S. pneumoniae 
serotype 3 (6303), which was purchased from the American Type Culture Collection 
(ATCC). Sp3 bacterial burdens in homogenized whole lungs were assessed by 
euthanizing mice at specified time points and counting serial dilutions of bacterial CFU. 
Tissue Collection 
Various samples were collected from mice after euthanasia by isoflurane 
overdose. Heparin-coated syringes were used for collection of blood from the inferior 
vena cava, and blood plasma was separated from erythrocytes by centrifugation at 1500 
rcf for 15 minutes at 4°C. Pleural fluid was collected by washing the pleural space with 3 
mL of PBS. For BALF protein samples, the trachea was cannulated with an 18-gauge 
angiocatheter (Becton Dickinson 381444), and the lungs were lavaged twice with 0.5 mL 
of PBS. For collection of lung protein, harvested lungs were homogenized in a bullet 
blender (Next Advance) in water containing protease inhibitor (Roche). Samples were 
centrifuged at 4°C and 10,000 rcf for 20 minutes, and supernatants were stored at -80°C.  
 For human samples, pathologist-determined normal lung tissue from 7 patients 
undergoing surgical lung cancer resection was collected under protocols approved by the 
Boston University institutional review committees. The tissues were immediately 
immersed in RPMI Medium and transported to the laboratory on ice. Informed consent 





For experiments requiring mouse lung single-cell suspensions, isolated lung lobes 
were minced with a razor blade then digested by shaking at 250 rpm and 37°C for 1 hour 
in digestion buffer containing type 2 collagenase (1 mg/mL, Worthington Biochemical), 
DNase I (150 µg/mL, Sigma), and CaCl2 (2.5 mM) in PBS.  Digested cells were passed 
through a 70 micron filter, and red blood cells were lysed in cell lysis buffer (Sigma). 
Single cell suspensions were then counted on a Luna Dual Fluorescence Cell Counter 
(Logos Biosystems) and used for flow cytometry and ex vivo stimulation assays.  
For human lung samples, the tissue was similarly processed into single cell suspensions 
by mincing and digestion under the same conditions as above but with a buffer 
containing: 0.2 µg/mL type A collagenase (Worthington Biochemical), 40 µg/mL DNase 
I (Sigma), 1 mM CaCl2, 50 µL/mL heat-inactivated FCS (Sigma), and 10 µL/mL HEPES 
(Thermo Fisher Scientific) in HBSS. Digested human lung tissue was passed through a 
cell strainer as above, then red blood cells were lysed using BD PharmLyse buffer 
according to the manufacturer’s instructions. Single cell suspensions were counted as 
above and analyzed via flow cytometry. 
Flow Cytometry 
To distinguish circulating (IV) from lung tissue (EV) cells, mice were injected i.v. 
with 2 µg of the indicated fluorescent anti-CD45 antibody 3 minutes prior to sacrifice and 
lung harvest. Single cell lung suspensions were prepared as above, with left and right 
lobes digested separately. Single cell spleen suspensions were obtained by filtering 




specified fluorescent antibodies (see Table 1) in FACS buffer (PBS containing 0.5% FBS 
and 2 mM EDTA) on ice in the dark for 30 minutes. After staining, all samples were 
resuspended in FACS buffer containing 7-AAD (BD Biosciences) live/dead stain at a 
1:100 dilution. Stained cells were assessed on LSR-II (BD Biosciences) or Cytek Aurora 
(Cytek Biosciences) flow cytometry analyzers. Controls in each experiment included 
unstained cells, single-stain UltraComp eBeads (Thermo Fisher Scientific) used for 
automatic compensation, and fluorescence minus one controls for each stain that 
preliminary experiments determined did not result in easily distinguished populations. 





Table 5. Antibodies used in flow cytometry analysis of mouse tissues. 
Marker Fluorophore/Conjugate Clone Vendor Product Number
IgA Biotin RMA-1 Biolegend 407003
B220 APC Fire 750 RA3-6B2 Biolegend 103259
B220 PerCpCy5.5 RA3-6B2 Biolegend 103235
CD11a APC M17/4 Biolegend 101119
CD11a PECy7 M17/4 Biolegend 101121
CD19 BUV395 1D3 BD Biosciences 563557
CD19 BV605 6D5 Biolegend 115539
CD19 BV421 6D5 Biolegend 115537
CD20 APC SA275A11 Biolegend 150411
CD38 PerCPef710 90 Thermo Fisher 46-0381-80
CD4 APC GK1.5 Biolegend 100411
CD43 BV750 S7 BD Biosciences 747277
CD43 APC S11 Biolegend 143207
CD44 BV421 IM7 BD Biosciences 563970
CD45 FITC 30-F11 Biolegend 103108
CD45 AF532 30-F11 Thermo Fisher 58-0451-82
CD45 PerCpCy5.5 30-F11 Biolegend 103131
CD45 BUV737 30-F11 BD Biosciences 748371
CD45.2 BUV737 104 BD Biosciences 612778
CD62L PECy7 MEL-14 Biolegend 104418
CD69 PE H1.2F3 Biolegend 104508
CD73 APC TY/11.8 Biolegend 127209
CD73 PE-Vio 770 TY/11.8 Miltenyi 130-103-055
CD80 BV421 16-10A1 BD Biosciences 562611
CXCR5 PE-eFluor 610 SPRCL5 Thermo Fisher 61-7185-82
GL7 Biotin GL7 Biolegend 144616
IgD PerCPef710 11-26c Thermo Fisher 46-5993-82
IgD AF488 11-26c Biolegend 405717
IgG1 FITC RMG1-1 Biolegend 406606
IgG2b FITC RMG2b-1 Biolegend 406705
IgG2c FITC polyclonal Southern Biotech 1079-02
IgG3 Biotin RMG3-1 Biolegend 406803
IgM PECy7 RMM-1 Biolegend 406514
IgM eF450 eB121-15F9 Thermo Fisher 48-5890-82
PD-L2 APC TY25 Biolegend 107210





Table 6. Antibodies used in flow cytometry analysis of human tissues. 
B and T Cell Depletion 
For circulating B cell depletion studies, mice were treated once with an anti-CD20 
monoclonal antibody (clone 5D2, Genentech) or a rat IgG2a isotype control antibody 
(BioXCell) i.p. (100 µg) and i.n. (100 µg). B cell depletion was assessed via flow 
cytometry either 4 days or two weeks after antibody treatment. In experiments to assess 
effects of anti-CD20 depletion on lung immunity to pneumococcus, mice were infected 
i.t. with Sp3 four days after treatment with anti-CD20 or the isotype control. 
For depletion of PD-L2+ B cells, experienced PZTD mice were treated once with 
i.t. (50 ng into the left lung lobe) and i.p. (50 ng) diphtheria toxin (Sigma, d0564) in 
sterile saline. Vehicle-treated mice were given i.t. and i.p. sterile saline. 
For CD4+ depletion studies, mice were treated with an anti-CD4+ monoclonal 
antibody (clone GK1.5) or a rat IgG2b isotype control antibody (both from BioXCell). 
Antibodies were diluted in sterile saline and administered i.p. (500 µg) and i.n. (100 µg). 
For depletion studies in µMT mice, antibodies were administered 72 and 24 hours prior 
Marker Fluorophore/Conjugate Clone Vendor Product Number
B220 BUV737 RA3-6B2 BD Biosciences 564449
CD19 FITC HIB19 Biolegend 302206
CD27 BV421 M-T271 BD Biosciences 562513
CD38 APCCy7 HB-7 Biolegend 356616
CD4 PECy7 RPA-T4 BD Biosciences 560649
CD69 PE FN50 Biolegend 310906
CD83 APC HB15e Biolegend 305311
IgD PerCPCy5.5 1A6-2 BD Biosciences 561315




to Sp3 challenge. For depletion studies during the initial pneumococcal exposures, 
antibodies were administered as indicated in Fig. 16A.  
For studies involving inhibition of leukocyte egress from tissues, mice were 
treated i.p. with 1 mg/kg body weight of FTY720 (Sigma, SML0700) every other day 
beginning 7 days following the first pneumococcal infection. 
ELISAs 
Pneumococcal-specific antibodies were measured in plasma, ex vivo culture 
supernatants, and BALF using a whole bacterial cell ELISA protocol based on the 
method described in (160). The indicated pneumococcal strain used as a capture antigen 
was grown overnight on blood agar plates and was then suspended in sterile PBS such 
that 1 x 107 CFU was added in 50 µL to coat each well of a 96-well plate. The acapsular 
pneumococcal strain used in the culture supernatant and BALF experiments was 
generated by Dr. Stephen Pelton at Boston University Medical Center and was derived 
from a serotype 3 parent strain. Plates were coated overnight at 4°C, then washed and 
blocked with 100 µL/well 1% bovine serum albumin in PBS for 2 hours at room 
temperature. Plates were again washed then incubated at room temperature for 2 hours 
with 50 µL of the indicated sample per well. Plasma samples were diluted as indicated. 
Ex vivo culture supernatants were not diluted. BALF samples were diluted 1:2. After 
washing, 100 µL per well of one of the following HRP-conjugated anti-mouse antibodies 
was added and incubated at room temperature for 2 hours: anti-total IgG (1:2000, R&D 
Systems, HAF007), anti-IgG3 (1:10,000, Abcam, ab97260), anti-IgG1 (1:10,000, Abcam, 




Abcam, ab97255), anti-IgA (1:2000, Thermo Fisher Scientific, RRID: AB_2533951), 
anti-IgM (1:2000, Thermo Fisher Scientific, RRID: AB_2533954). The plate was then 
washed and developed with 3,3',5,5'-tetramethylbenzidine (TMB) substrate (R&D 
Systems). The reaction was stopped with 2N sulfuric acid stop solution (R&D Systems). 
The optical density of each well at 450 nm was determined using a microplate reader 
(BioTek Synergy LX Multi-Mode). 
IL-17 was measured in lung homogenates of µMT mice using a DuoSet IL-17 
ELISA kit (R&D Systems, DY421) performed according to the manufacturer’s 
instructions. CXCL13 and CXCL12 were measured in lung homogenates using DuoSet 
ELISA kits (R&D Systems; DY470 and DY460, respectively) according to the 
manufacturer’s instructions. 
Pneumococcal Opsonization 
For opsonization with plasma, Sp3 was added to 500 µL of pooled plasma from 
mice that received i.n. Sp19 or saline 4-8 weeks prior until the mixture reached an optical 
density of 0.3. For opsonization with BALF, 25 µL of a 1:4 dilution of Sp3 at an optical 
density of 0.3 was mixed with approximately 300 µL of pooled BALF from mice that 
received i.n. Sp19 or saline 4-8 weeks prior. For both experiments, the mixture was 
rotated for 1 hour at 4°C, then bacteria were spun down at 9600 rpm for 9 minutes. 
Bacterial pellets were resuspended in 500 µL of sterile saline, then 50 µL was instilled 
i.n. into each recipient mouse. Recipient mice were healthy naïve mice that had never 
been exposed to pneumococcus or saline previously. Lung Sp3 CFU were determined 24 




Ex vivo B Cell Stimulation and ELISpot 
Mice were given an i.v. injection of 2 µg PE anti-CD45 (Biolegend, RRID: 
AB_312971) 3 minutes before sacrifice and harvest of lung left lobes and spleens. Single 
cell suspensions of lung and spleen tissue were procured as described above, including 
red blood cell lysis. Cells in lung tissue that were not protected from the i.v. stain (i.e., 
were bound to PE anti-CD45) were then selected out using an EasySep Mouse PE 
Positive Selection Kit (StemCell Technologies, 17666) according to the manufacturer’s 
instructions. Following selection of lung cells, all cells were resuspended at 4x106/mL in 
CTL-Test B Medium (ImmunoSpot, Cellular Technology Ltd.) containing Resiquimod 
(R848) and IL-2 (ImmunoSpot, CTL-mBPOLYS-200) and 1% L-glutamine (Thermo 
Fischer Scientific) for stimulated samples or CTL-Test B Medium with 1% L-glutamine 
alone for unstimulated controls. Cells were incubated on 12-well plates (1 well per tissue 
sample) for 4-5 days at 5% CO2 and 37°C. Following culture, supernatants of each well 
were collected and stored at -80°C for pneumococcal-specific antibody analysis. Cells 
were collected and used for total IgG ELISpot assays using the Immunospot Mouse IgG 
Single-Color ELISpot kit following the manufacturer’s instructions. Developed ELISpot 
plates were visualized and counted on a BioSpot S5 Macro Analyzer using the 
Immunospot software package (Cellular Technology Ltd.). Prior to the automated 





Whole Blood RNA-Seq 
Facial vein blood from 10 naïve and 10 experienced mice that had been rested for 
6 weeks was collected into anticoagulant-coated tubes (BD 365974). RNA was extracted 
from the whole blood using the Mouse RiboPure-Blood RNA Isolation Kit (Thermo 
Fisher Scientific, AM1951) according to the manufacturer’s instructions. RNA was 
purified and a cDNA library was generated using a TruSeq Stranded Total RNA Library 
Prep Globin (Illumina, 20020612). Single-end 50 base pair read length sequencing was 
performed on an Illumina HiSeq 2500. Libraries were constructed, quantified, and 
sequenced by the Tufts University Core Facility in Genomics (http://tucf-
genomics.tufts.edu/). Illumina fastq files were quality-trimmed using FastQC and 
Trimmomatic 0.36 (161) and were then aligned to the GRCm38.p5 build of the mouse 
genome (https://www.gencodegenes.org/) using STAR 2.5.3a (162). Only uniquely 
aligned reads, which accounted for 47%–56% of all reads from the sample set were used 
for downstream analysis. The relatively low proportion of uniquely aligned reads was due 
to high amounts of sequenced non-coding RNA species such as mt-Rnr2 and Rn7sk. 
Indexed bam files were then converted to raw gene counts using HTSeq (163) and the 
GENCODE M15 gene annotation reference. The Bioconductor package DESeq2 (164) 
was used for statistical evaluations of expression differences between naïve and 
experienced mice.  
Microscopy 
Lungs of euthanized experienced and naive mice were prepared for 




were then embedded and flash frozen in OCT. Frozen blocks were cut into 8 micron 
sections and were then stained with the following primary antibodies: rabbit anti-CD4 
(1:500, Abcam, ab183685); rat anti-B220 (1:1000, BD Pharmingen, 553084), followed 
by staining with Alexa 488 donkey anti-rabbit secondary antibody (1:1000, Jackson 
Immunoresearch, 711-546-152), Alexa 594 donkey anti-rat secondary antibody (1:1000, 
Jackson Immunoresearch, 712-586-153), and DAPI. Slides were imaged at room 
temperature with a Leica DM4 microscope and Leica DFC 7000T camera, and were 
acquired with Leica LAS X software. Images were captured using a 20x objective with a 
numerical aperture of 0.55 or a 40x objective with a numerical aperture of 0.8. 
For confocal imaging of HEV markers, 10 micron thick frozen sections of murine 
lungs or mediastinal lymph nodes prepared as above were used. Staining and imaging 
were performed as previously described (165, 166). The primary antibodies used were rat 
anti-PNAd (1:1000, Santa Cruz Biotechnology, sc-19602) and rabbit anti-CD34 (1:200, 
Abcam, ab81289), with a DAPI counterstain. Images were captured with Fluoview 
acquisition software on an Olympus Fluoview 10i scanning laser confocal microscope 
using a 10x objective, numerical aperture 0.4. Photomultiplier tube gain and laser power 
settings were such that no signal was visible on isotype control sections.  
All images were processed in ImageJ/FIJI using identical look-up table settings 
for all images of the same magnification. 
Statistical Analyses 
Statistical analyses were performed using GraphPad Prism 8.0. Each graph 




individual point on a graph corresponds to an individual animal/sample. Plots displaying 
data as individual points and summary data depicted as violin plots are shown with 
medians indicated. Other summarized data are shown as means with standard deviations. 
Mann-Whitney U tests were used to assess comparisons of two groups, while three or 
more groups were compared using either a Kruskal-Wallis test with Dunn’s multiple 
comparisons test or a two-way ANOVA with a Holm-Sidak multiple comparisons test, as 
indicated. Where multiple comparisons tests were used, all possible comparisons were 
made unless otherwise indicated in the figure legend. The FDR was calculated to control 
for multiple comparisons in RNA-seq data. Two-sided P values were calculated in all 







CHAPTER THREE: LUNG RESIDENT MEMORY B CELLS PROTECT 
AGAINST BACTERIAL PNEUMONIA 
Portions of the data and text in this chapter have been submitted as a manuscript to the 
Journal of Clinical Investigation.  
Introduction 
Humans evolved alongside a vast array of microbial organisms and environmental 
antigens. Consequently, our immune system is highly adaptable, undergoing long-term 
systemic and mucosal remodeling following exposure to commonly encountered external 
stimuli (167). Traditional specific pathogen-free laboratory mice immunologically 
resemble infant humans and lack immune features observed in healthy adults, including 
resident lymphocytes in non-lymphoid tissues, but gain these more human-like immune 
features upon pathogen exposures (136, 167).   
Tissue resident immune cells comprise a group of non-circulating leukocytes that 
act as a front-line barrier of defense, especially at mucosal sites of constant 
environmental antigen exposure such as the lung. Although multiple immune cell types, 
including innate immune cells, may be resident, the long-term protective potential of 
adaptive memory cells makes resident memory lymphocytes particularly intriguing. TRM 
cells populate mucosal surfaces in response to various bacterial and viral pathogens and 
provide rapid local protection against reinfection (168). In the lung, TRM cells are 




been extensively studied over the last two decades, it remains uncertain whether 
complementary BRM cells are a common feature at mucosal sites.  
MBCs located in mucosal tissues play important roles in mice and humans, but 
generally are found in organized lymphoid structures such as the gut-associated lymphoid 
tissue (170) and human tonsils/adenoids (171). In the female mouse reproductive tract, 
HSV immunization generates local TRM cells without concurrent BRM cell formation, 
indicating that the presence of mucosal TRM cells does not always correlate with 
establishment of a BRM cell pool (172). Lung BRM cells are elicited by influenza 
infections in mice (112, 139). These B cells do not recirculate (139) and provide 
enhanced protection when adoptively transferred compared to splenic flu-specific MBCs 
(112). However, the detailed location of these BRM cells in the lung has not been 
described. Notably, influenza generates long-lasting iBALT in mice (155). Like other 
organized lymphoid structures, iBALT has been shown to support MBCs but is not a 
typical feature of healthy adult human lungs (153, 157). Lungs of rhesus monkeys 
recovered from asymptomatic H1N1 infection are enriched for TRM cells but not for 
BRM cells, a finding attributed to the likely lack of iBALT from such low virulence 
infections (173). Thus, whether lung BRM cells are unique to iBALT-containing mouse 
lungs after influenza or are a common feature of the lung adaptive immune cell landscape 
remains to be determined. 
Both viral and bacterial lung infections impart a large burden of disease globally 
and in the US, especially among children and the elderly, for whom pneumonia leads to 




(pneumococcus), comprised of at least 100 serotypes defined by polysaccharide capsule, 
represents the most common bacterial cause of CAP (10). Essentially all children, even 
those given pneumococcal vaccination, are colonized or infected multiple times with 
pneumococcus before the age of 2 (174). These natural exposures generate serotype-
independent (heterotypic) immune protection (175). Heterotypic antibodies, LLPCs, and 
lung TRM cells contribute to naturally acquired immunity to pneumococcus (67), but a 
role for MBCs has yet to be investigated. Given that virus-elicited MBCs can harbor 
cross-reactive specificities against mutated viral strains (149, 176), we hypothesized that 
MBCs may play a similar role in immunity against multiple pneumococcal serotypes. 
Therefore, we undertook this study to address the fundamental gaps in knowledge 
regarding the existence of lung BRM cells outside the setting of flu-recovered mouse 





Effects of resolved pneumococcal pneumonias on circulating cell transcriptomes 
The resolution of pneumococcal pneumonias in mice provides serotype-
independent lung protection against subsequent pneumonia conferred in part by CD4+ 
TRM cells and remodeled alveolar macrophages (74, 177, 178). We suspected that 
additional immune changes elicited by pneumococcal exposures remained to be 
identified. The remodeled immunity in specific pathogen free mice exposed to pathogen-
rich pet store mice was defined by a profound change in circulating blood leukocytes, 
evident in their transcriptomes (167). To investigate whether respiratory infections with 
S. pneumoniae elicited similar systemic changes, we infected mice in the left lung lobe 
with pneumococcal serotype 19F (Sp19F) twice at a one-week interval (Fig. 3A). Such 
infections are self-limiting, and animals fully recover without the aid of antibiotics or 
supportive treatment (177). Control mice were concurrently given saline instillations. 
Infected and control mice were rested for at least 4 weeks. Previously infected mice were 
referred to as “experienced,” while control mice were referred to as “naïve.” As described 
above, experienced mice contain serotype-independent (heterotypic) immune protection, 
as evidenced by their ability to clear a serotype mismatched challenge infection with 
pneumococcal serotype 3 (Sp3), which grows uncontrollably in naïve mice (Fig. 3B).  
However, unlike the radically transformed blood transcriptomes of so-called “dirty” mice 
compared to naïve laboratory mice (167), the whole blood transcriptomes of uninfected 
experienced and naive mice in our model were essentially identical (Fig. 3C-3D). Only 




and experienced mice (Lpp, Pmaip1, Nt5c, and Arfgap2), none of which exhibited a fold 
change greater than 1.36 (0.76, 1.36, 1.22, and 1.23, respectively). Thus, while prior 
studies revealed new cells and altered resident cell phenotypes in the lungs of mice 
recovered from such Sp19F infections (74, 177, 178), the circulating cell transcriptomes 
were unchanged. 
 
Figure 3. Pneumococcal exposures provide lung protection without extensive 
changes to the blood transcriptome. (A) C57BL/6 mice were exposed to i.t. 
pneumococcus (Sp19F) or saline in the left lung lobe twice at a one week interval then 
allowed to recover for at least four weeks, at which point they were referred to as 
experienced and naïve mice, respectively. (B) Experienced and naïve mice were 
challenged with i.t. pneumococcus (Sp3) for 24 hours before lung bacterial burdens were 
assessed (Mann-Whitney test, P=0.0006). (C and D) Principal component analysis (C) 
and read counts (D) from RNA sequencing of whole blood collected from the same naïve 
and experienced mice as in (B) prior to Sp3 challenge. Point size in (C) is proportional to 






MBCs in pneumococcus-experienced lungs without iBALT 
The lack of systemic transcriptomic differences between naïve and experienced 
mice led us to focus on unexplored cell types in the lung itself that may be contributing to 
improved immunity in experienced mice. Depleting CD4+ TRM cells before the Sp3 
challenge only partially abrogates lung protection in experienced mice (74). Based on 
these findings and the recent descriptions of lung BRM cells in mice recovered from 
influenza (112, 139, 149), we hypothesized that MBCs may be found in pneumococcus-
experienced lungs. At 4 weeks after the last Sp19F exposure, the lungs of experienced 
and naïve mice are histologically normal, and do not contain visible iBALT structures by 
H & E staining (74). However, immunofluorescence analysis revealed B220+ cells in 
small clusters around bronchovascular bundles in experienced (Fig. 4A-E), but not naïve 
(Fig. 4F), mice. Organized aggregates consisting of B and T cell zones were not 
observed, although individual CD4+ cells were apparent in or near B cell clusters to 
varying degrees (Fig 4B,D,E, white arrows). We also stained lung sections of 
experienced mice for CD34 and peripheral node addressin (PNAd), which co-stain HEVs 
found in well-organized lymphoid structures such as lymph nodes (Fig. 4G) or lung 
iBALT (153). Although the lung sections stained brightly for the vascular endothelial 
marker CD34, we did not observe PNAd staining, indicating HEVs were not present in 





Figure 4. Pneumococcal exposures elicit B cell clusters in lungs without 
HEVs. (A to F) Immunofluorescence of representative experienced (20x: A,C,E; 40x: 
B,D) and naïve (20x: F) lungs [B220 (red), CD4 (green, indicated by white arrows), 
nuclei (DAPI; blue)]. (G to J) Frozen sections of an experienced mouse mediastinal 
lymph node positive control (G) or of lungs from three experienced mice (H-J) were 
stained for nuclei (DAPI, blue), the blood vessel marker CD34 (green), and peripheral 






To phenotype these lung B cells, we used flow cytometry with an i.v. anti-CD45 
stain to distinguish circulating from lung leukocytes (gating schemes for all flow 
cytometry experiments in Fig. 5). A population of CD19+ cells protected from the i.v. 
stain, defined as extravascular (EV) B cells, was observed in the lungs of experienced but 
not naïve mice (Fig. 6A). The EV B cells in experienced mice were predominantly IgD-, 
while the intravascular (IV) B cells positive for the i.v. stain in the same mice were 
largely IgD+ (Fig. 6B-C). Additionally, the EV lung IgD- B cells, but not the EV IgD+ B 
cells, were significantly increased by experience, and there was no effect of experience 
on the IV B cells in these lung digests (Fig. 6D). These data suggest that the lung EV B 
cell compartment after pneumococcal exposures is enriched for non-naïve B cells, which 
we hypothesized were comprised largely of memory cells. Consistent with this 
hypothesis, the number of IgD- EV B cells in experienced lungs remained constant for as 
long as 12 weeks after the last Sp19 infection before declining by 6 months post-
exposure, when the significant difference in lung B cell numbers between experienced 
and naïve mice was lost (Fig. 6E). Moreover, all the EV IgD- B cells in experienced mice 
were CD38+, an MBC phenotype in mice (Fig. 6F) (106). Altogether, these results 
indicate that repeated pneumococcal exposures in mice elicit MBCs within the lung tissue 





Figure 5.  Flow cytometry gating schemes used to analyze mouse lung B cells. (A) 
Gating used for all flow cytometry data except that noted for (B), collected on the BD 
LSR II. (B) Gating used in a subset of mice from Fig. 6 D-E and all mice in Fig. 6F, 






Figure 6. Pneumococcal exposures elicit extravascular MBCs in the lung. (A) 
Representative gating of i.v. CD45+ CD19+ cells (“IV B cells”) and i.v. CD45- CD19+ 
cells (“EV B cells”) in lungs of naïve and experienced mice at least 4 weeks after 
pneumococcal exposure. (B) Representative IgD expression on IV and EV B cells in 
experienced lungs. (C) The percent of IV and EV B cells that are IgD- in experienced 
lungs (Mann-Whitney test, P<0.0001). (D) Percentages of IgD+ and IgD- B cells of live 
lung cells in the IV and EV compartments of naïve and experienced mice analyzed 
between 4 and 12 weeks after the previous Sp19 exposure (2-way ANOVA, *P=0.029, 
**P=0.0006, ***P<0.0001). (E) The number of IgD- EV B cells in naïve and 
experienced lungs at the indicated times after lung exposure (2-way ANOVA, *P=0.01, 




IgD- B cells (each red curve from one of five separate mice) and on EV CD45- cells 
(shaded curve, representative). 
 
Resident phenotype of lung MBCs elicited by pneumococcal exposures 
The lack of i.v. CD45 staining of the lung B cells in experienced mice indicated 
that these cells were excluded from circulation at the time of assay. We hypothesized that 
the lung MBCs represent a resident immune cell pool, and considered whether they bore 
surface markers similar to lung TRM cells (CD69+CD11abrightCD62LloCD44+) (74). 
Consistent with prior reports on lung BRM cells (112, 139), many of the EV B cells in 
experienced mice expressed the lymphocyte residence marker CD69 and the integrin 
CD11a (Fig. 7A, left panel). Compared to IV B cells, EV B cells had lower expression of 
the lymphoid organ homing molecule CD62L and higher expression of the glycoprotein 
CD44 (Fig. 7A, right panel). The similarity in surface marker profiles between the MBCs 
in pneumococcus-experienced lungs and lung TRM cells reported in many experimental 
systems indicates that the MBCs observed here are likely to be resident cells and that 
there may be a common lymphocyte residency signature.  
Since we were modeling lobar pneumonias, and prior studies revealed 
immunological changes in the lung occur locally (74, 139, 178), we examined the lobe 
specificity of the lung B cell phenotypes. The initial Sp19F exposures were restricted to 
the left lung lobe. EV B cells in the left lobes of experienced mice contained significantly 
greater CD69+ fractions (Fig. 7B) and had significantly higher expression of CD11a (Fig. 
7C) compared to the EV B cells from all other groups. The increase in IgD- EV B cells 




increase in the contralateral right lobes that did not have prior infections (Fig. 7D). Thus, 
prior experience with pneumococcal infection changed only the EV B cells of the 
involved lobe.  
The phenotype of these B cells suggested they were BRM cells. In parabiosis 
experiments, cells that fail to relocate to the relevant organ in the parabiont via 
anastomosed circulatory systems are designated as tissue-resident rather than tissue-
homing cells (139). The restriction of B cell phenotypes to the involved lobe and not the 
contralateral lobes (Figs. 7B-D) matches the parabiosis logic for concluding that these 
cells are lung resident rather than lung homing. However, we recognized an alternative 
hypothesis may be that these B cells are not resident, but instead are circulating B cells 
that home only to previously infected tissue. We therefore wanted to test whether the EV 
lung MBCs stably remained in the lung compartment. To do so, we leveraged the fact 
that murine IgG2a anti-CD20 antibodies deplete CD20+ B cells in a circulation-
dependent manner (179). Both IV and EV lung B cells expressed CD20 (Fig. 7E, IgG- 
treated mice). An anti-CD20 antibody administered i.n. and i.p. reached the EV lung B 
cells and remained bound, as shown by blocking of binding of a directly labeled APC-
CD20 antibody to EV lung B cells in mice treated two weeks prior with anti-CD20 (Fig. 
7E). The anti-CD20 antibody effectively depleted IV B cells but had no effect on EV B 
cells, observed at both 4 days and 2 weeks after anti-CD20 administration (Fig. 7F-G). 
Because anti-CD20 bound but did not deplete the EV lung B cells, we conclude that these 




the lung MBCs elicited by bacterial pneumonia are lung resident rather than lung homing 
cells. 
 
Figure 7. Lung B cells in experienced mice are resident. (A) Representative flow 
cytometry plots showing expression of CD69, CD11a, CD62L, and CD44 on IV and EV 
IgD- lung B cells in experienced mice. (B) Percent CD69+ of EV IgD- B cells in the 
exposed left lung lobe and control right lung lobes of naïve and experienced mice (1-way 
ANOVA, *P=0.0054, **P=0.0021, ***P<0.0001). (C) The median fluorescence intensity 
(MFI) of CD11a on EV IgD- B cells in the exposed left lung lobe and control right lung 
lobes of naïve and experienced mice (1-way ANOVA, *P=0.0047, **P=0.0017, 
***P<0.0001). (D) The fold change in EV IgD- lung B cells between saline and 




dot represents the average fold change in one experiment containing ≥ 3 naïve and 3 
experienced mice (Mann-Whitney test, P=0.036). (E) Binding of a fluorescent anti-CD20 
antibody to lung B cells from mice treated two weeks previously with isotype control IgG 
or anti-CD20 (5D2 clone). (F and G) Representative flow cytometry plots (F) and 
quantified CD19+ cells (G) in lung compartments 4 days or 2 weeks after anti-CD20 or 
IgG treatment of experienced mice (Kruskal-Wallis test, *P=0.002). 
 
Human lung BRM cells 
Since pneumococcus and influenza are both common causes of lung infection in 
humans (10) and both lead to deposition of lung BRM cells in mice (Figs. 4-7 and (139)), 
we hypothesized that human lungs may contain BRM cells. Disease-free samples from 
lung tissue wedge resections or lobectomies were assessed via flow cytometry (Fig. 8A). 
Consistent with a prior report (136), significantly more CD4+ T cells than B cells were 
observed in the human lungs (Fig. 8B). Of the CD19+ cells in these lungs, the majority 
(~65%) were positive for the human MBC marker CD27, and the remaining cells were 
mostly IgD+ (Fig. 8C). Most of the MBCs (CD19+CD27+) as well as the CD4+ T cells 
in these lung samples were CD69+, whereas most naïve B cells (CD19+IgD+) in the 
same lungs were not (Fig. 8D). The percentages of lung CD4+ T cells that were CD69+ 
in our samples matched well to lung T cell data from studies of humans with no known 
lung disease (136, 180), suggesting our samples fairly represented human lung 
immunology. The majority of MBCs in these lungs were class-switched, with only ~17% 
expressing IgM (Fig. 8E). The CD69+ MBCs were negative for CD38 (Fig. 8F), 
indicating they were not GC or plasma cells (181). In addition to being a residence 




were negative for CD83 (Fig. 8F), another marker of B cell activation (182). Therefore, it 
is likely that CD69 is a marker of resident, as opposed to recently activated, cells in this 
context. These data provide evidence that human lungs contain class-switched BRM 
cells. 
 
Figure 8. Human lungs are enriched for B cells bearing a resident memory 
phenotype. (A) Pathologist-determined normal tissue from wedge resection or biopsy 
samples from humans with lung cancer were collagenase digested and analyzed via flow 
cytometry using the gating scheme shown. (B to F) Various cell surface phenotypes of B 
and T cells in the human lung digests. (B) The percent of CD4+ and CD19+ cells among 
live, single cells (Mann-Whitney test, *P=0.0023). (C) The percent of CD27+ cells 
among all CD19+ cells and among naïve (CD19+IgD+) B cells (Mann-Whitney test, 
*P=0.0025). (D) The percent of CD69+ cells among CD4+ cells, memory B cells 
(CD19+CD27+), and naïve B cells (Kruskal-Wallis test, *P=0.021, **P=0.049). (E) The 
percent of memory B cells that are class-switched and the percent that are IgM+ (Mann-
Whitney test, *P=0.0079). (F) The percent of resident memory B cells 





Lung BRM cell isotypes and memory marker expression 
After observing that pneumococcal exposures elicit lung BRM cells, we wanted to 
more deeply explore the phenotypic and functional aspects of these cells. Although the 
EV lung B cell compartment included naïve B cells (IgD+IgM+), a larger fraction was 
IgM+IgD- than in the spleen or the blood (Fig. 9A). Additionally, and in contrast to the 
spleen and blood compartments, an appreciable proportion of class-switched B cells was 
observed in the lung EV tissue, highlighting the enrichment of switched memory cells at 
this site (Fig. 9A). Of the class-switched EV lung B cells, the majority were of an IgG 
isotype, with a small fraction of IgA+ B cells (Fig. 9B).  
In mice, the markers PD-L2, CD73, and CD80 distinguish functional MBC 
phenotypes (109). In lung B cells of experienced mice, the expression of all three markers 
was restricted, as expected, to IgD- cells, and the EV compartment was heavily enriched 
with B cells bearing these markers compared to IV B cells in the same mice (Fig. 9C). 
Importantly, the EV B cells in experienced lungs predominantly expressed more than one 
of these markers (Fig. 9D-E). Co-expression of at least two of these three memory 





Figure 9. Experienced lungs are enriched in class-switched MBCs bearing multiple 
memory markers. (A) Distribution of naïve, IgM+IgD-, and class-switched B cells in 
experienced lungs and spleens (2-way ANOVA comparing isotypes across 
compartments, N=3 for spleen, 5 for lung; *P<0.0022 vs. spleen, 0.0009 vs. IV lung; 
**P<0.0001 vs. either compartment). (B) Experienced EV lung IgM-IgD- B cell isotypes. 
N=5. (C-E) Representative flow plots from experienced lungs showing MBC marker 
expression on IgD- EV B cells (C) and co-expression (D) as quantified in (E), where 
numbers of triple negative (TN), single positive (SP), or double or triple positive (DP/TP) 
B cells are shown (2-way ANOVA comparing each marker category between naïve and 




Antibody secretion from lung BRM cells 
To test whether the lungs of experienced mice contained more MBCs that could 
be reactivated into ASCs, we stimulated total splenic B cells and EV lung B cells from 
naïve or experienced mice. After 4 days of ex vivo culture followed by IgG ELISpot 
analysis, spots representing reactivated MBCs were detected more frequently in wells 
containing stimulated cells from experienced mouse lungs compared to unstimulated cells 
from experienced mice or stimulated cells from naïve mice (Fig. 10A-B). Although 
stimulation also elicited ASC differentiation in spleen cells, there was not a significant 
difference in the number of spleen IgG ASCs between naïve and experienced mice (Fig. 
10B). Supernatants from ex vivo cultures of stimulated experienced, but not stimulated 
naïve, mouse lung cells contained IgG and IgM antibodies that bound to an acapsular 
pneumococcal isolate, indicating they were specific to serotype-independent 
pneumococcal antigens. Again, stimulated spleen cells from both naïve and experienced 
mice were able to produce pneumococcus-reactive IgG and IgM, with no significant 
differences between the groups (Fig. 10C). These results show that the spleens of naïve 
mice contain B cells that can be stimulated to secrete antibody against pneumococcal 
antigens, and there is no significant enrichment of such B cells after lung exposure to 
pneumococcus. These splenic B cells in naïve and experienced mice are likely comprised 
of innate-like marginal zone or B1 B cells surviving culture only with stimulation and 
able to produce pneumococcus-binding antibodies (183). In the lung, however, prior 
pneumococcal exposure is required to generate pneumococcus-specific MBCs. To see 




in vivo, we analyzed the BALF of experienced mice at baseline and 96 hours after Sp3 
challenge. The BALF of experienced mice post-challenge contained significantly more 
IgA, IgG, and IgM antibodies able to bind an acapsular pneumococcal strain (Fig. 10D). 
These findings provide evidence that BRM cells in the experienced lung are reactivated 
by a heterotypic pneumococcal challenge to locally secrete serotype cross-reactive 
antibodies. Thus, the lungs of mice previously exposed to pneumococcus are enriched 






Figure 10. Lung BRM cells are poised to secrete antibody. (A-B) Total IgG ELISPOT 
image (A) and counts (B) of spleen and EV lung B cells after ex vivo culture (Kruskal-
Wallis test for each organ, *P=0.028, **P= 0.0035 for spleen, 0.006 for lung). Vertical 
lines in (A) separate images within a group obtained from different plates. (C) 
Pneumococcus-specific antibody levels in ex vivo culture supernatants from (A-B) 
(Kruskal-Wallis test for each isotype within each organ, *P=0.0039 for IgG, 0.0064 for 
IgM). (D) Pneumococcus-specific antibody in experienced BALF at baseline or after Sp3 
infection (Mann-Whitney test for each isotype, N=15 for baseline, 8 for 96 hours, 





Reliance of serotype-independent protection on B cell immunity 
The above data led us to hypothesize that B cells in the lung may contribute to 
serotype- independent pneumococcal immunity. Recovery from pneumococcal infections 
later protects mice from a serotype mismatched challenge with Sp3 (Fig. 3 and (74)). We 
found that this protection is partially dependent on B cell-mediated immunity, as 
evidenced by the increased bacterial burdens (Fig. 11A) and morbidity (Fig. 11B) in 
experienced B cell deficient (µMT) mice compared to experienced C57BL/6 (B6) mice 
after Sp3 infection. Notably, although µMT mice in our model develop a slightly 
diminished lung TRM cell pool compared to B6 mice (Fig. 11C-D), experienced µMT 
mice still generate as much lung CD4+ T cell-derived IL-17A after Sp3 challenge as 
experienced B6 mice do (Fig. 11E-F and (74)). Therefore, the less robust protection of 
experienced µMT mice is not due to a failure to generate effective lung T cell memory, as 
has been observed in other infection settings (184).  
Although experienced µΜΤ mice lacking all mature B cells have diminished 
protection, which B cells contribute to this are unknown. Since the anti-CD20 antibody 
effectively depletes circulating B cells but not lung BRM cells (Fig. 7), we tested whether 
anti-CD20 treatment affected lung defense in experienced mice. Depletion of all 
circulating B cells in experienced B6 mice via four days of anti-CD20 treatment had no 
effect on 24-hour clearance of Sp3 (Fig. 11G). These data suggest that aspects of B cell 








Figure 11. Experienced µMT mice have intact lung CD4+ TRM cell responses but 
impaired serotype-independent lung defense. (A) 24-hour lung Sp3 burdens in naïve 
and experienced B6 or µMT mice (2-way ANOVA, *P=0.013, **P=0.0004, 
***P<0.0001). (B) Weight loss after Sp3 challenge in experienced B6 and µMT mice (2-
way ANOVA comparing mouse strains within each time point, N=16 B6 and 9 µMT, 
*P=0.0004). (C) Flow cytometry gating scheme used to assess lungs of experienced B6 
and µMT mice for EV T cells bearing a resident memory phenotype (CD69+CD11ahi). 
(D) Results obtained from gating in (C), showing the percent of EV lung CD4+ T cells 
that were CD69+CD11ahi in lungs of experienced B6 and µMT mice (Mann-Whitney 
test, *P=0.0002). (E) IL-17A levels determined by ELISA in whole lung homogenates of 
naïve and experienced µMT mice after 24 hours of Sp3 pneumonia (Mann-Whitney test, 
*P<0.0001). (F) IL-17A levels determined by ELISA in whole-lung homogenates of of 
experienced µMT mice treated with either an IgG isotype control or a CD4+ T cell 
depleting antibody (GK1.5) prior to 24 hours of Sp3 challenge (Mann-Whitney test, 
*P=0.032). (G) 24-hour lung Sp3 burdens in naïve and experienced B6 mice treated four 
days prior with isotype control or anti-CD20 (2-way ANOVA, *P=0.0024 for IgG, 
0.0027 for anti-CD20). 
 
Pre-existing anti-pneumococcal antibodies 
The finding that µMT mice have diminished protection in our model while anti-
CD20-treated mice remain protected could be due to contributions of pre-formed anti-
pneumococcal antibodies secreted by long-lived plasma cells. µMT mice lack both pre-
existing antibodies and MBCs (158), and plasma cells do not express CD20 and are 
therefore not depleted by anti-CD20 treatment (185). Given that serotype-independent 
pneumococcal protection in experienced mice is limited to the exposed lung lobe and is 
not seen in the contralateral lobe, systemic factors such as antibodies that should be able 
to distribute equally to both lung lobes are not sufficient for protection (74). However, 
this does not exclude the possibility that such antibodies contribute to lung defenses. 
Consistent with prior studies (62), lung exposure to pneumococcus resulted in plasma 




serotype (Fig. 12A), indicating a systemic heterotypic response to these lung infections. 
The BALF of experienced mice also contained heterotypic anti-pneumococcal antibodies 
(Fig. 12B), although the distribution of isotypes observed was markedly different than 
that in the plasma of the same mice.  
To determine whether these antibodies have the capacity to contribute to 
protection, we incubated Sp3 with plasma or BALF from uninfected experienced or naive 
mice before instilling the pre-opsonized bacteria into the lungs of naïve recipients. Pre-
opsonization of Sp3 with BALF of experienced versus naïve mice resulted in no 
difference in the lung bacterial burden of recipient mice (Fig. 12C). This finding may be 
a reflection of the extremely low titers of serotype cross-reactive BALF antibodies 
observed in our model compared to other settings where specific BALF antibody titers 
can be much higher, on the order of 1:100 or even 1:1000 (186, 187). In contrast, mice 
receiving bacteria pre-opsonized with experienced plasma were able to control bacterial 
growth compared to recipients of bacteria pre-opsonized with naive plasma (Fig. 12D), 
indicating that circulating antibodies have some ability to protect against Sp3 challenge. 
However, neither recipient group was able to clear the Sp3 compared to input levels, 
confirming that pre-existing antibodies are not sufficient to confer the full protection 
observed in our model. Contributions from other immune components, including memory 
T (74) and possibly memory B cells in the lungs, are required for optimal serotype- 





Figure 12. Pre-existing heterotypic antibodies in the plasma are capable of 
contributing to serotype-independent anti-pneumococcal defense. (A-B) Plasma (A) 
or BALF (B) collected from uninfected naïve and experienced mice was assessed for 
titers of Sp3-reactive antibodies of the indicated isotypes via whole-cell pneumococcal 
ELISA. N=3 for naïve mice and 6 or more for experienced mice. (C-D) BALF (C) or 
Plasma (D) of experienced or naïve mice was used to pre-opsonize Sp3 prior to bacterial 
instillation in naïve mice and determination of 24 h lung CFU (Mann-Whitney test, 
*P=0.01). 
 
B1 B cells in the lung 
B1 B cells, which are known to contribute to immunity against pneumococcus in 
mice (29), are also not thoroughly depleted by anti-CD20 treatment (179). Additionally, 
the pleural fluid is rich in B1 B cells, which can migrate to the lung in response to a 
primary pneumococcal exposure (183). We considered whether a lack of pleural fluid B1 




there are no substantial differences in pleural fluid total B cells (Fig. 13A) or B1 B cells 
(Fig. 13B) after pneumococcal experience, and we observe no change in the experienced 
lung B1 B cell proportion upon Sp3 infection. These findings indicate it is unlikely that 
pleural B1 B cells are an important component of serotype-independent pneumococcal 
immunity in our model. 
 
Figure 13. B1 B cells are not changed in the pleural fluid of experienced vs. naïve 
mice and do not infiltrate the lung upon Sp3 challenge. (A) The number (left) and 
percent (right) of CD19+ cells in the pleural fluid of naïve and experienced C57BL6/J 
mice as determined by flow cytometry. (B) Representative flow cytometry plots showing 
the similar distributions of B1 and B2 cells in the pleural fluid of naïve and experienced 
C57BL6/J mice. (C) The percent of EV lung IgM+ B cells with a B1 phenotype at 
baseline and after 1-2 days of Sp3 pneumonia in naïve and experienced C57BL6/J mice. 





Pneumonia protection by lung BRM cells 
The above data indicate that aspects of B cell immunity, but not circulating B 
cells, contribute to lung defense in experienced mice. These findings also suggest that 
lung TRM cells (Fig. 11) and pre-existing antibodies (Fig. 12) are not sufficient for full 
protection, and that B1 B cells are unlikely to play a large role in our model of serotype -
independent pneumococcal immunity (Fig. 13). This led us to hypothesize that the non-
circulating lung MBCs play a functional role in bacterial clearance from experienced 
lungs. However, there are no means of selectively deleting these cells. Since more than 
half of the IgD- lung EV B cells are PD-L2+ (Fig. 9C-D), we devised a strategy to 
deplete PD-L2+ B cells specifically. By crossing CD19-Cre mice into the PD-L2-
ZsGreen-TdTomato-diphtheria toxin knock-in and inducible knockout (PZTD) 
background (159), all PD-L2+ and only PD-L2+ cells are fluorescent, with CD19-PD-
L2+ cells in both Cre- and Cre+ mice expressing the fluorescent ZsGreen protein, while 
CD19+PD-L2+ cells in Cre+ mice express the fluorescent TdTomato protein as well as 
the diphtheria toxin (DT) receptor (Fig. 14A-B). Resolution of Sp19F infections in these 





Figure 14. Lung PD-L2+ MBCs are also established by pneumococcal experience in 
a genetically modified mouse model. (A) Schematic depicting the cell phenotypes 
observed in Cre- and Cre+ offspring of PZTD mice crossed with CD19-cre mice. (B) 
Flow cytometry gating scheme used in genetically modified mouse lungs. (C) 
Representative flow plots of EV lung B cells in naïve and experienced Cre+ mice with no 
DT treatment. 
 
Treating experienced Cre+ mice with DT eliminated this PD-L2+ B cell 
population from the lungs (Fig. 15A-B). In contrast, DT treatment of experienced Cre- 




pleural PD-L2+ B cells in Cre+ mice, although only 53% of pleural PD-L2+ B cells were 
depleted by DT (Fig. 15C). However, as described above, pleural fluid B cells do not 
obviously change in response to prior pneumococcal experience (Fig. 13A-B), nor does it 
appear that pleural B1 cells infiltrate the lungs of naïve or experienced mice challenged 
with Sp3 (Fig. 13C), so these cells are unlikely to mediate improved immunity in 
experienced mice. Circulating Sp3-specific antibody levels did not differ between DT-
treated experienced Cre- and Cre+ mice (Fig. 15D). To determine roles of PD-L2+ B 
cells in experienced mice, we allowed resolution of Sp19F infections in Cre+ and Cre- 
mice, after which DT was delivered to all mice to deplete lung PD-L2+ BRM cells from 
Cre+ but not Cre- mice. Three weeks later, all mice were challenged with Sp3 (Fig. 15E). 
The Cre+ mice exhibited significantly more morbidity as assessed by weight loss during 
four days of Sp3 infection (Fig. 15F). This morbidity was likely driven by the increased 
bacterial burdens in the lungs of Cre+ mice, since the majority of Cre- but not Cre+ mice 
had reduced bacteria to below the limit of detection over the 4 days of infection (Fig. 






Figure 15. Lung MBCs are required for optimal serotype-independent anti-
pneumococcal lung immunity. (A) Representative flow plots of EV lung B cells in 
experienced Cre+ mice with or without DT. (B) Quantification of PD-L2+ EV B cells in 
lungs of experienced Cre- and Cre+ mice with or without DT (2-way ANOVA, N= 7 for 
vehicle-treated Cre- mice, 3 for DT-treated Cre- mice, 8 for vehicle-treated Cre+ mice, 
and 10 for DT-treated Cre+ mice, *P=0.029). (C) The percent of pleural fluid and EV 
lung B cells that are PD-L2+ in Cre+ mice with or without DT treatment (2-way 
ANOVA, *P<0.0001). (D) Plasma collected 96 hours after Sp3 infection from 
experienced DT-treated Cre- and Cre+ mice was assessed for Sp3-reactive antibodies of 
the indicated isotypes via whole-cell pneumococcal ELISA. N=12 for Cre- mice and 9 for 




Timeline of infections, DT administration and Sp3 challenge in genetically modified 
mice. (F) Weight loss after Sp3 challenge in DT-treated experienced Cre- and Cre+ mice 
(2-way ANOVA comparing genotypes within each time point, N=11 per genotype, 
*P=0.0093). (G) 96-hour lung Sp3 burdens in DT-treated experienced Cre- and Cre+ 
mice (Mann-Whitney test, *P=0.0004). Square=female; circle=male for Cre+ group. One 











These studies show that mouse lungs recovered from pneumococcal infections 
contain BRM cells that contribute to serotype-independent anti-pneumococcal protection. 
In light of these results, combined with the evidence that influenza also elicits lung BRM 
cells (112, 139, 149) and our finding that normal human lung tissue is enriched with 
BRM-like cells, we propose that BRM cells are a common component of the lung 
adaptive immune cell repertoire. 
 Although we consistently observed lung B cells in small clusters near 
bronchovascular bundles, we did not find evidence of tertiary lymphoid tissues in these 
pneumococcus-recovered lungs, which lacked large lymphocyte aggregates, organized B 
and T cell zones, and high endothelial venules. This differs from influenza, which elicits 
these features in addition to lung BRM cells (139, 155). Distinct populations of lung 
TRM cells in influenza-recovered mouse lungs display differing tendencies to be 
associated with areas of iBALT (188). However, B cell studies in the context of influenza 
have not reported lung B cells outside of iBALT (188-190), and it is therefore unclear 
whether influenza-generated lung BRM cells reside exclusively in these structures. The 
current pneumococcus studies dissociate BRM cells from iBALT and reveal definitively 
that lung BRM cells can be components of histologically unremarkable lungs. 
In addition to our studies of pneumococcus-experienced mice, we observed cells 




exposed to both pneumococcus and influenza in addition to a wide variety of other 
respiratory pathogens. The phenotype of lung B cells observed in this study, where 50-
70% of the lung B cells expressed the memory marker CD27, differs from that typically 
observed in blood of adult humans, where the majority of B cells are naïve (191). We 
conclude that the antigen-experienced lung represents a site of BRM cell accumulation 
across species. 
       We chose to give mice initial pneumococcal exposures directly in the lung, as 
opposed to using a colonization model. Whether the outcomes after repeat i.t. exposures 
in mice truly mimic the lungs of humans, who are frequently colonized and less 
frequently experience true pneumonia events, may be questioned. However, there is 
evidence that colonization alone can change BALF macrophage and T cell populations in 
humans, and the density of pneumococcal colonization has been shown to correlate with 
the amount of pneumococcal DNA found in human BALF (70, 192). These findings lead 
us to believe that the repeated colonization events experienced by most humans likely 
result in changes to the lung immune cell environment similar to those elicited by lobar 
exposures in mice. 
Epidemiological evidence suggests that natural human exposures to 
pneumococcus confer serotype-independent immunity against both colonization and 
invasive pneumococcal disease (67, 175). The difficulties in scaling up current serotype-
specific pneumococcal vaccines to cover all serotypes has led to extensive interest in 




protection. Studies addressing this in mice have highlighted roles for lung and nasal TRM 
cells, remodeled alveolar macrophages, plasma antibodies, and long-lived bone marrow 
plasma cells (67, 177). A role for MBCs in serotype-independent immunity has not 
previously been investigated. The PZTD mouse model afforded us a unique opportunity 
to assess the effects of inducible depletion of memory marked (PD-L2+) B cells while 
leaving naïve B cells and pre-existing antibodies intact. Depletion of CD19+PD-L2+ B 
cells in pneumococcus-experienced mice led to a substantial loss of serotype-independent 
lung protection.  
This result differs from those of a prior study in which pneumococcal colonization 
of mice protected against serotype-matched lung infection. In that setting, while LLPCs 
are crucial, MBCs are dispensable (62). These findings may reflect the particular 
importance of MBCs in responses to related but not identical infections. This partitioning 
of function has been observed for influenza and West Nile viruses, for which pre-existing 
antibodies protect against homologous virus rechallenge, while reactivated MBCs confer 
immunity against an antigenically distinct virus (149, 176). We postulate that MBCs, 
especially those in the lung, also play an important role in the heterotypic immune 
response to bacterial respiratory pathogens. This would imply that vaccines against 
pathogens that rapidly mutate or comprise many subtypes should be designed with a goal 
of eliciting B cell memory in addition to circulating antibody.  
A limitation to our studies is the difficulty in distinguishing the functional 




and B1 B cells. Plasma cells have been observed within lungs recovered from viral 
infections (153), and although they are outside the scope of this work, it is important to 
consider whether such cells may have contributed to our observations. Some mature 
plasma cells express CD19 (193). However, the high CD38 expression on EV mouse 
lung CD19+IgD- B cells and lack of CD38 expression on most human lung 
CD19+CD27+ B cells indicates that CD19+ plasma cells were not major components 
recovered in uninfected collagenase digested lungs (106). 
In humans, anti-CD20 depletion of B cells is a treatment for B cell malignancies. 
However, previous studies have noted a resistance of solid tissue B cell populations to 
this therapy (194), and it is possible that depletion-resistant BRM cells in the lung 
contribute to the fairly low rates of infection among anti-CD20-treated patients (195). A 
similar observation was noted in studies using Alumtizimab for T cell depletion, which 
did not lead to the expected increases in skin infections due to the presence of protective 
TRM cells (196). Interestingly, there is some evidence that anti-CD20 therapy is effective 
against BALT lymphomas, which may imply that unlike BRM cells outside of organized 
lymphoid structures, lung B cells within BALT are more accessible to the circulation 
(197).  
The COVID-19 pandemic raises new questions about lung immunology. It will be 
of interest to determine whether resolution of SARS-CoV-2 infection results in lung 
BRM cells. Relating to the evidence that lung BRM cells are essential components of 




human lungs contain cross-reactive BRM cells elicited by the endemic human 
coronaviruses, and if so, whether those BRM cells influence the outcome of SARS-CoV-
2 infection. 
Many aspects of BRM cells demand further investigation, including factors 
leading to their recruitment and retention, mechanisms by which they provide protection, 
their immunoglobulin repertoire, and whether BRM cells, like TRM cells, are found 
across a wide range of organ systems in mice and humans. Despite these unknowns, a 
burgeoning body of evidence including the present study has begun to shed light on the 
previously unrecognized importance of BRM cells in the lung. Our findings lead to a 
more complete picture of the natural lung defenses that pneumococcal exposures generate 
and that are crucial for subsequent pneumonia protection. Defining these protective 
mechanisms in healthy hosts will guide studies into what aspects of this protection are 
lost with age or comorbidities. And as many mucosal vaccine development strategies 
have begun to focus on eliciting resident memory cells, this knowledge will also be 






CHAPTER FOUR: THE ESTABLISHMENT OF LUNG BRM CELLS AFTER 
PNEUMOCOCCAL PNEUMONIA 
Introduction 
Often, the ultimate goal in biomedical and immunological research is the 
translation of basic findings into applications for human health. For example, evidence 
that TRM cells provide superior protection compared to circulating cells in animal 
models of natural infections (198-200) has led to early attempts at eliciting TRM cells 
with vaccination approaches. Parenteral vaccination of mice with killed pneumococci has 
recently been found to establish nasal CD4+ TRM cells that protect against 
pneumococcal colonization (76). Intravenous, but not intramuscular or intradermal, 
administration of a malaria vaccine in non-human primates generated liver CD8+ TRM 
cells that were crucial for durable sterilizing immunity (201). In many cases, this 
translational focus has been possible because of prior studies elucidating the signals 
required for TRM cell establishment, which have been carried out in a variety of organs 
and infection settings (202-205). The basic observation that genital HSV-2 infection-
induced CXCL9 and CXCL10 are required for anti-viral CD8+ TRM cell recruitment has 
been applied to a “prime-pull” vaccination approach where parenteral vaccination is 
followed by topical chemokine administration. This method effectively eliminated 
clinical disease development in mice (206) and decreased recurrent HSV-induced disease 




The kinetics of TRM cell establishment have also been characterized in various 
settings, providing crucial information on the optimal time after immunization to give a 
pull or boost to best mimic the TRM cell generation that occurs in a natural infection. In 
the HSV-2 studies mentioned above, appropriate timing of chemokine administration was 
determined by previous work demonstrating that CD4+ T cells are recruited to the 
vaginal mucosa 3-4 days post-infection, prior to CD8+ T cells, which enter the tissue at 
days 4 and 5. Interferon produced by the early recruited CD4+ T cells is responsible for 
the production of local chemokines on day 4 that subsequently drive recruitment of CD8+ 
T cells that establish tissue residency (208). In the lungs of mice following a single 
influenza virus infection, a rapid influx of CD4+ T cells protected from i.v. antibody 
labeling is observed as early as 3 days post-infection, and these cells peak between days 
10 and 14. Contraction of this population occurs in tandem with clearance of viral antigen 
over a period of three weeks, at which point steady-state numbers of TRM cells are 
reached (169). As in the case of HSV-2, influenza-specific CD4+ T cells enter the lung 
around day 5 post-infection, a day earlier than CD8+ T cells, and interferon-gamma 
derived from lung CD4+ T cells is crucial for functional CD8+ TRM cell formation 
(209).  
Given the newness of the BRM cell field, it is perhaps unsurprising that very little 
is known about the signals required for establishment of these cells in the lung or 
elsewhere. What we do know comes from studies in the context of murine influenza 
infections. The majority of lung BRM cells in this setting express the chemokine receptor 




the lung after various infections (210, 211). Establishment, but not maintenance, of 
influenza-specific lung BRM cells is dependent on CD40:CD40L interactions with T 
cells (139). Multiple groups have observed fairly consistent kinetics of lung B cell 
recruitment following influenza infection in mice. Initial detection of influenza-specific 
MBCs in the lung occurs at day 7 post-infection, followed by a peak at days 14-15 and 
then a steady decline over about three weeks until equilibrium numbers of lung MBCs are 
reached (112, 139, 148). Whether lung BRM cells outside of the context of influenza 
infections develop with similar kinetics may indicate if there is a conserved pattern of 
BRM cell establishment across infection types or if establishment dynamics are context-
dependent. 
As described in the previous section, one of the characteristic features of 
influenza infections in mice is the induction of iBALT, but to what extent influenza-
specific lung BRM cells are found within iBALT is not known. These structures support 
persistent GC reactions within the lung beginning as early as day 10 post-infection and 
lasting for several weeks thereafter (139, 149, 186), and these GCs are responsible for 
production of influenza strain cross-reactive MBCs (149). Whether GCs within the lung 
are required for lung BRM cell accumulation in all infection settings has not been 
explored. Additionally, several distinct signaling pathways are known to be important for 
the recruitment of B cells into iBALT (212, 213), but it is unclear whether any of those 
pathways are relevant to lung BRM cells that are maintained independently of tertiary 




Therefore, this study was undertaken to determine the requirements for and 
kinetics of lung BRM cell formation in a very different infection setting: here we studied 
lungs following infection with S. pneumoniae, which does not elicit iBALT but does 
generate a long-lasting and non-circulating population of MBCs within the mouse lung 
(Chapter 3).  A better understanding of the signals and timing involved in BRM cell 
formation will enable future studies of tissue resident B cells to mimic the progress that 






CD4+ T cell dependence of lung BRM cell establishment 
Typical MBC responses, whether of extrafollicular origin or from a GC, require 
the help of CD4+ T cells at some stage during development (86). However, quiescent 
antigen-specific B cells that resemble MBCs can arise from proliferating precursor cells 
(probably a B1 B cell subset) in T cell-independent responses to polysaccharide antigens 
such as the pneumococcal capsule (214). We previously showed that respiratory 
exposures to S. pneumoniae in mice generate lung BRM cells that are required for 
serotype-independent pneumococcal immunity (Chapter 3). The cross-reactivity of 
antibodies secreted by these MBCs led us to hypothesize that they were specific to 
pneumococcal species conserved protein antigens, as opposed to the serotype defining 
capsular polysaccharide. However, there are other highly conserved pneumococcal 
polysaccharide antigens, such as cell wall polysaccharide (215). Additionally, the 
expression of defining MBC markers such as PD-L2, CD73, and CD80 has not been 
assessed on T-independent MBCs (216), so the expression of these markers on BRM 
cells in pneumococcus recovered lungs does not exclude them from a T-independent 
origin.  
We used a previously established mouse infection model in which 6-8 week old 
C57BL6/J mice were infected twice at a weekly interval with i.t. Sp19F, with each 
infection resulting in a self-limiting pneumococcal pneumonia cleared within 5 days (74, 




lung BRM cells (Chapter 3). To test whether establishment of lung BRM cells after 
pneumococcal exposures was dependent on CD4+ T cells, we administered the CD4+ T 
cell depleting antibody GK1.5 or an isotype control antibody to mice before, during, and 
immediately after the two exposures to i.t. Sp19 (Fig. 16A). At day 35, flow cytometry 
with an i.v. stain to exclude circulating leukocytes from the analysis was used to assess 
whether memory B and T cells accumulated in the lungs after pneumococcal exposures. 
As expected, total lung CD4+ T cells and CD4+ lung TRM cells (CD11ahiCD69+), which 
were intact in experienced mice treated with an isotype control antibody, were nearly 
undetectable at day 35 in GK1.5-treated mice (Fig. 16B). GK1.5 treatment during 
memory establishment also significantly reduced lung BRM cells (EV CD19+CD69+ 
cells) in proportion and number to levels seen in naïve mice at day 35 (Fig. 16C). These 
findings definitively show that lung BRM cells generated by pneumococcal pneumonia in 
mice are T cell-dependent and therefore likely specific to a pneumococcal protein 







Figure 16. Lung BRM cell establishment requires the presence of CD4+ T cells 
during initial infections. (A) Prior to, during, and after initial Sp19 exposures, mice 
were treated i.p. or i.n./i.p. as indicated with the CD4+ T cell depleting antibody GK1.5 
or with an isotype control antibody. Lung cell populations were assessed four weeks after 
the second Sp19 infection. (B) The percent (left) and number (right) of EV CD4+ T cells 
in lungs of naïve mice and experienced mice treated with GK1.5 or an isotype control 
antibody as described in (A). (C) The percent (left) and number (right) of EV 
CD19+CD69+ cells in lungs of naïve mice and experienced mice treated with GK1.5 or 
an isotype control antibody as described in (A). Comparisons all made by one-way 
ANOVA; *P<0.05, **P<0.01, ***P<0.001.  
 
Kinetics of lung BRM cell recruitment after multiple pneumococcal exposures 
We previously showed that initial pneumococcal infection protects mice from a 




one pneumococcal exposure with 1x106 CFU of Sp19F was not enough to provide this 
protection; at least two exposures at a one week interval were required. Because we had 
also shown that lung PD-L2+ MBCs are needed for serotype-independent lung protection 
(Chapter 3), we wondered whether multiple pneumococcal exposures are necessary to 
establish a lung B cell population. When we compared the lung B cell populations of 
mice given either one or two i.t. Sp19 exposures four weeks previously, we observed a 
statistically significant increase in total lung B2 cells and in lung BRM cells (EV 
CD19+CD69+) only in mice that received two prior infections (Fig. 17A-B).  This 
observation confirmed that at least two exposures to Sp19 are required to establish a 
substantial lung BRM cell pool.  
To gain a more thorough understanding of the kinetics of lung BRM cell 
establishment in our model, lungs of mice were analyzed via flow cytometry at various 
time points following one (Fig. 17C, “1x Sp19 group”) or two (Fig. 17D, “2x Sp19 
group”) Sp19 infections. A large influx of B2 B cells was observed as early as day 1 and 
peaked at day 3 after the initial Sp19 infection. In 1x Sp19 mice, these infiltrated B cells 
began to wane in number between days 3 and 7, and by day 10 returned nearly to baseline 
levels (Fig. 17C). In contrast, the second Sp19 infection generated another influx of B 
cells into the lung, which again peaked three days later but was over twice as large in 
magnitude as the influx generated by the first infection. As the inflammation resolved, 
the number of lung B cells dropped precipitously through day 35 but then stabilized, with 
around 10,000 EV B cells maintained for at least 6-8 weeks (Fig. 17D). This pattern was 




increase in the proportion of B cells in the lung expressing CD69, which is probably a 
marker of activation within the first three days of infection (217). However, at time points 
after two infections where CD69 is more likely to represent a marker of residence, the 
proportion of CD69+ B cells remained significantly higher than at corresponding time 
points after one infection. These data show that the second Sp19 infection results in a 
larger initial B cell influx and a residual resident B cell population not elicited by a single 






Figure 17. Two pneumococcal infections are required to generate a robust lung 
BRM cell population. (A-B) The number of total EV lung B2 cells (A) and EV lung 
CD69+ B2 cells (B) after one or two Sp19 infections four weeks prior (one-way 
ANOVA; **P<0.01, ***P<0.0001). (C-D) The number of total EV lung B2 B cells at the 
indicated time points following one (C) or two (D) Sp19 infections. (E) The percent of 




two (blue curve) Sp19 infections (comparisons between the 1x and 2x curves at each time 
point made via multiple t-tests; *P<0.05,***P<0.001).  
 
Timing and requirements for lung class-switched MBC expansion 
Using the same experimental design as in Fig. 17, we also analyzed class-
switched and memory marked EV lung B cells after one or two Sp19 infections. Each 
infection resulted in a transient increase in naïve (IgD+IgM+) B cells (Fig. 18A). In 1x 
Sp19 mice, the distribution of naïve, IgM+, and class-switched B cells returned to 
approximately baseline proportions 8 to 10 days later (Fig. 18A, top row). Interestingly, 
after the influx of naïve B cells generated by the second Sp19 infection, an increase in 
class-switched B cells in the lung was observed at day 14 (7 days after the second 
infection), and this increase was maintained through day 35 (Fig. 18A, bottom row). The 
proportion of class-switched B cells was significantly higher in the 2x Sp19 group than in 
the 1x Sp19 group at days 14, 24, and 35, and while the lungs of mice in the 2x group 
contained significantly more class-switched B cells than naïve lungs, lungs of mice after 





Figure 18. The proportion of class-switched lung MBCs expands one week after a 
second Sp19 infection. (A) The proportions of EV lung B cells that are naïve (black), 
IgM+IgD- (pink), or class-switched (blue) at the indicated time points after one or two 
Sp19 infections. Each pie slice represents the average from 6 mice at that time point, 
except on the graphs for day 10, where each represents the average from 3 mice 
(comparisons between the 1x and 2x groups at each time point from day 8 onward made 
via multiple t-tests; *P<0.05). (B) The percent of EV lung B cells that are class-switched 
four weeks after one or two Sp19 infections (one-way ANOVA; *P<0.05). ns, not 
significant. 
 
In looking at the distribution of memory markers on lung B cells over time, we 
first looked only at 2x Sp19 mice and divided EV lung B cells into three populations. The 
first population consisted of all naïve (IgD+) B cells, which, as mentioned above, 




19A). No time point significantly differed in naïve B cell content in the lung compared to 
baseline, likely due to the wide spread in the naïve B cell proportions in uninfected 
mouse lungs. The second population, termed double negative (DN) MBCs, consisted of 
IgD- B cells that expressed CD38, and can therefore be classified as MBCs (106), but did 
not express either of the memory markers PD-L2 or CD73. As explained in the preceding 
sections, PD-L2 and CD73 are two markers of mouse MBCs that are co-expressed on B 
cells that tend to be class-switched and contain more BCR mutations (97). The DN 
MBCs did not appreciably change in proportion over the time course of the study (Fig. 
19B), though there was again a wide spread in how frequent this population was in naïve 
lungs. The third population, double positive (DP) MBCs, were IgD-CD38+PD-
L2+CD73+ B cells. Between 3 and 7 days after the second infection, this population 
significantly increased in the lung, indicating the MBC pool was likely becoming 
progressively more mutated and class-switched (Fig. 19C). The latter was confirmed by 
the observation that the proportion of DP MBCs that were IgM+ decreased significantly 
from day 8 to days 14-35 (Fig. 19D). Interestingly, one Sp19 exposure also elicited a 
small but significant increase in DP lung MBCs between 3 and 7 days post-infection (Fig. 
19E). After this brief rise in number, the population stabilized right away, without the 
continued increase seen in the 2x Sp19 group. This increase in DP MBCs in the 1x group 
lungs did not appear to correlate with the expected increase in class-switched lung MBCs, 







Figure 19. MBCs bearing multiple memory markers accumulate in the lungs 
starting one week after a second Sp19 infection. (A-C) The proportion of EV lung B 
cells that are naïve (A), DN MBCs (IgD-CD38+PD-L2-CD73-) (B), or DP MBCs (IgD-
CD38+PD-L2+CD73+) (C) at indicated time points following two Sp19 infections (one-
way ANOVA comparing each time point to the day 0 baseline group; *P<0.05). (D) The 
proportion of DN MBCs (gray) and DP MBCs (purple) that are IgM+ at the indicated 
time points following two Sp19 infections (two-way ANOVA; **P<0.01, 
****P<0.0001). (E) The proportion of EV lung B cells that are DP MBCs at indicated 




to the day 0 baseline group; *P<0.05). (F) The proportion of DN MBCs (gray) and DP 
MBCs (purple) that are IgM+ at the indicated time points following one Sp19 infection. 




The preceding data showing that a second Sp19 infection results in a larger and 
more rapid accumulation of class-switched and likely mutated MBCs within the lung 
after day 10 led us to wonder whether there might be lung-localized GC reactions in the 
2x Sp19 group. We examined lungs of 1x and 2x Sp19 mice at various time points for B 
cells bearing either a “pre-GC” phenotype (GL7+CD38hi) (89, 218) or a GC B cell 
phenotype (GL7+CD38lo) (Fig. 20A). In 1x mice, a very small number of pre-GC and GC 
B cells were observed in the lungs at day 3 (around 50 GC B cells in a whole lung on 
average). GC B cells in 1x lungs peaked at day 7 (around 450 GC B cells in a whole 
lung) but were not maintained through day 35 (Fig. 20C-D, black points). In contrast, a 
second Sp19 infection led to a significant accumulation of pre-GC (Fig. 20B) and GC 
(Fig. 20C) B cells in the lung, peaking at day 10 for pre-GC B cells and day 14 for GC B 
cells (around 5,000 GC B cells per lung). Although the number of GC B cells steeply 
declined after day 14, at day 35 a few hundred remained in the lungs of 2x Sp19 mice, 
while 1x Sp19 lungs contained essentially none (Fig. 20D-F). Because GC B cells are 
known to lack many homing receptors that allow for recirculation and mucosal migration 
(219, 220), it is likely these GC B cells are indicative of ongoing local GC reactions in 
the lungs, as opposed to being a recruited population from SLO GCs. Therefore, these 
data indicate that between 3 and 17 days after the second Sp19 infection, lungs of 2x 




for weeks after the resolution of local inflammation. Notably, GL7+CD38hi pre-GC 
phenotype B cells in 2x Sp19 lungs at days 10 and 14 vastly outnumber GC B cells at any 
point (Fig. 20 B-C). This GL7+CD38hi phenotype has been shown to mark precursor B 
cells that can enter a GC and typically become class-switched MBCs, however, these 
cells also have the potential to directly differentiate into IgM+ or class-switched MBCs 
independently of a GC reaction (89). This GL7+CD38hi population may therefore 
contribute to both GC B cells and GC-independent lung MBCs, a hypothesis that will 









Figure 20. Pre-GC and GC B cells are observed in mouse lungs following two Sp19 
infections. (A) Representative flow cytometry plot showing the gating of pre-GC B cells 
(EV CD19+CD38+GL7+) and GC B cells (EV CD19+CD38-GL7+) in the lung of a 




cells (B) and GC B cells (C) in lungs of mice at the indicated time points following one 
or two Sp19 infections (comparisons between the 1x and 2x groups at each time point 
from day 8 onward made via multiple t-tests; *P<0.05). (D) The number of lung GC B 
cells at day 35 following one or two Sp19 infections (Mann-Whitney test; **P<0.01). (E-
F) Representative flow cytometry plots showing gating of pre-GC B cells and GC B cells 




 The window between days 10 and 14 (3 and 7 days after the second infection, 
respectively) in the above experiments seemed to be a period of importance for the development 
of B cell memory in the lung. In this window, the percentage of lung B cells expressing CD69 
reaches its final value, the initial accumulation of class-switched and DP MBCs in the lung is 
observed, and lung GC B cells reach their peak numbers. Two possible scenarios that might 
explain these findings are: 1) the initial Sp19 infection seeds a small number of B cells in the 
lung that, upon second infection, undergo a proliferative burst and form local GCs that lead to 
rapid class-switched and DP MBC accumulation locally, or 2) the initial Sp19 infection primes 
the lung in some way to enhance recruitment or retention of B cells such that after the second 
infection, more MBCs formed in SLOs enter the lung and stay and/or more naïve B cells are 
recruited to join lung GC reactions and contribute to local MBC generation. To try and 
distinguish between these possibilities, we treated mice recovered from an initial Sp19 infection 
with FTY720, an inhibitor of lymphocyte exit from SLOs and tissues (221), before, during, and 
after the second Sp19 infection (Fig. 21A). This protocol allows normal establishment of lung 
cells elicited by the first infection, but recruitment of new cells upon the second Sp19 exposure 
is prevented in FTY720-treated mice. In this experiment, days 13 and 17 corresponded to days 




resulted in a large reduction in circulating B cells at either 3 or 7 days after the second Sp19 
infection (Fig. 21B). In vehicle-treated mice, an increase in non-naive and CD69+ B cells 
between days 3 and 7 post-second Sp19 was seen, consistent with results from the kinetic 
studies in Fig. 19 (Fig. 21 C-D, black dots). However, treatment with FTY720 abrogated these 
increases; while vehicle and FTY720-treated mice had similar naïve and IgD-CD69+ B cell 
populations in the lungs three days after the second Sp19 infection, four days later neither a 
decrease in naïve nor an increase in IgD-CD69+ B cells in the lungs was observed in the 
FTY720-treated group (Fig. 21C-D, blue dots). The induction of local GCs between 3 and 7 
days after the second infection was also not seen in FTY720-treated mice based on GC B cell 
percent and number (Fig. 21E-F). Together, these data indicate that cells established in the lung 
by the first Sp19 infection are not sufficient to drive the phenotypic changes in the lung B cell 











Figure 21. Continued influx of immune cells into the lung during and after the 
second Sp19 infection is required to generate lung GC reactions and class-switching. 
(A) Prior to, during, and after a second Sp19 infection, mice were treated with i.p. 
FTY720 or with vehicle alone. Lung cell populations were assessed three (day 13) and 
seven (day 17) days following the second Sp19 infection. (B) The percent of CD19+ 
lymphocytes in the blood of vehicle or FTY720-treated mice. Data from day 13 and day 
17 shown together (Mann-Whitney test, **P<0.01). (C-E) The percent IgD+ (C), percent 
IgD-CD69+ (D), and percent GC B cells (E) among EV lung B cells in vehicle- (black) 
or FTY720- (blue) treated mice at day 13 and day 17 (two-way ANOVA; *P<0.05). (F) 
The number of GC lung B cells in vehicle- (black) or FTY720- (blue) treated mice at day 
13 and day 17 (two-way ANOVA; *P<0.05). ns, not significant. 
 
 
CXCL13 correlation with lung BRM cell recruitment 
 The FTY720 experiment data suggested to us that recruitment of B cells from 
SLOs after the second Sp19 infection played a crucial role in generating a robust lung 
BRM cell compartment. Therefore, we next wanted to explore what chemokine signals 
may be playing a role in this recruitment. Most prior studies of mechanisms by which B 
cells are recruited to the lungs have been in settings of iBALT.  
 After influenza infection in mice, induction of IL-1 or type 1 interferon can 
induce stromal cell production of CXCL13, which is crucial for the recruitment of naïve, 
CXCR5+ B cells to form lung GC reactions and establish iBALT (212, 222). This 
recruitment pathway occurs independently of CXCL12, chemokine (C-C Motif) ligand 
19 (CCL19), CCL21, and TFH cells, and is not required for maintenance of lung GC, 
only establishment. In the context of sterile lung inflammation or mucosally delivered 
tuberculosis antigen plus adjuvant, IL-17 produced by CD4+ T cells is required to induce 
CXCL13 expression in the lung and establish iBALT (223, 224). Again, this IL-17 signal 




pathway of iBALT formation occurs in mice infected i.n. with a modified vaccinia virus 
(213). This CXCL13-dependent iBALT contains FDCs, indicating it is well-organized 
and mature. In contrast, lung infection of mice with Pseudomonas aeruginosa elicits IL-
17 production from gamma-delta T cells in the lung, which leads to stromal cell-derived 
CXCL12 production (213). In this study, CXCL12 (and not CXCL13) was required for 
formation of iBALT that does not contain FDCs, and the authors propose that different 
pathogens lead to iBALT with varying levels of organization and varying chemokine 
requirements for formation.   
 Although we have previously shown that there are not iBALT structures in 2x 
pneumococcus-experienced lungs at day 35 (Chapter 3), we hypothesized that some of 
the same mechanisms known to be important for B cell recruitment into iBALT might 
also be at play in the establishment phase for BRM cells in our model. Since mechanisms 
of lung B cell recruitment appear to vary by type of pathogen, we set out to determine the 
initial signals that may be responsible for bringing B cells into the lung after 
pneumococcal exposures in mice.  
Because the published pathways of iBALT formation rely on either CXCL13 or 
CXCL12, we wanted to determine whether expression of either of these chemokines was 
induced in lungs of mice after pneumococcal infections. Whole lung homogenates of 
mice were analyzed by ELISA at various time points after one or two Sp19 infections. 
One to 3 days after a second Sp19 infection, significantly higher levels of CXCL13 
protein were observed in lung homogenates compared to baseline levels at day 0 (Fig. 




increase was not statistically significant and was neither as large nor as protracted as the 
increase induced by the second Sp19 infection one week later. In contrast to CXCL13, 
CXCL12 protein levels in lung homogenate did not statistically vary from baseline after 
one or two Sp19 infections (Fig. 22B). An important caveat in the interpretation of these 
results is that ELISA analysis of bulk lung homogenates does not allow for assessment of 
the micro-localization of these chemokines within the lung, which may be as important as 
total chemokine production. Follow-up studies should use microscopy to assess 
chemokines in the context of the lung architecture to validate these findings. However, 
we generally took these data to indicate that CXCL13 may play an important role in the 
enhanced recruitment of B cells to the lung that occurs after a second Sp19 infection. We 
then assessed expression of the CXCL13 receptor, CXCR5, on EV B cells in the lung at 
various time points and saw that both one and two Sp19 infections resulted in significant 
increases in CXCR5+ B cells within the lungs 1 and 2 days post-infection (Fig. 22C). 
However, the influx that occurred following the second infection was three times as large 
in magnitude and was longer lasting, with a significant increase in CXCR5+ B cells over 
baseline observed at one week after the second, but not the first, Sp19 exposure. The fact 
that CXCL13 protein presence in the lung preceded a significant influx of CXCR5+ B 
cells in the lung EV tissue is compelling evidence that, as in many other settings of lung 
infection, CXCL13 plays an important role in B cell recruitment to the lung after 
pneumococcal infections as well. The enhanced production of this chemokine after a 
second Sp19 infection suggests that remodeling of a CXCL13-producing cell population 




upon reinfection. The cell types and upstream signals involved in CXCL13 production 
and the importance of this signaling axis for establishment of various BRM cell subsets 





Figure 22. Lung CXCL13 levels and CXCR5+ B cells are elevated following a 
second Sp19 infection. (A-B) CXCL13 (A) and CXCL12 (B) protein as detected by 
ELISA in whole lung homogenates of mice collected at the indicated time points 
following one (black curve) or two (blue curve) Sp19 infections (one-way ANOVA 
comparing each time point to the day 0 baseline group; *P<0.05). (C) The number of EV 
CD19+CXCR5+ B2 cells in lungs of mice at the indicated time points following one 
(black curve) or two (blue curve) Sp19 infections (crosses indicate significant results 
(P<0.05) for a one-way ANOVA comparing each time point to the day 0 baseline group. 
Stars indicate significant results (P<0.05) for multiple t-tests comparing matched time 






The research described in this chapter is ongoing, but results obtained so far 
provide insight on the signals required for establishment of MBCs in the lung after 
pneumococcal pneumonia. We have shown that lung BRM cells are T cell-dependent and 
thus likely specific to a pneumococcal protein antigen as opposed to a species conserved 
polysaccharide. Furthermore, two Sp19 infections are necessary for the establishment of 
a lung BRM cell pool, while one is not sufficient. The second Sp19 infection drives an 
increase in class-switched and PD-L2+CD73+ MBCs within the lung, which, based on 
prior literature, are likely to contain affinity matured BCRs and secrete antibody upon 
reactivation (97). These phenotypes may result from the lung-localized GC reactions that 
occur around a week after the second Sp19 infection. Whatever lymphocytes are 
established within the lung by the initial pneumococcal exposure are not sufficient to 
proliferate and form a BRM cell pool locally upon second infection, since FTY720 
treatment after the first Sp19 infection abrogates the increase in non-naïve B cells, 
CD69+ B cells, and GC B cells that normally occurs between 3 and 7 days post-second 
infection. This finding highlights the importance of B cell recruitment during the second 
Sp19 infection, which may be largely mediated by CXCL13, since this chemokine is 
induced within the lung at higher levels following a second Sp19 infection compared to 
the first, and its expression precedes an influx of CXCR5+ B cells into the lung 1-2 days 
later.  
As mentioned above, GL7+CD38hi “pre-GC” phenotype B cells can either enter a 




must be done to test the following hypotheses, it is tempting to speculate that the 
relatively large number of GL7+CD38hi cells at days 10 and 14 compared to the much 
lower number of GC B cells at day 14 indicates that only a small number of pre-GC B 
cells receive the appropriate signals in the lung to enter a GC reaction, and many or 
possibly most of the pre-GC B cells instead become extrafollicular MBCs. This would 
perhaps account for the large proportion of lung MBCs that are IgM+ (Chapter 3), since 
extrafollicular MBCs are often, though not always, unswitched (119). This theory may 
also help explain the slow accumulation of class-switched MBCs after day 14 (Figs 18A 
and 19D); GCs in the lung that develop at day 14 may output MBCs that are 
predominantly class-switched by days 24 and 35. It is also worth noting that the number 
of CXCR5+ B cells recruited at day 10 approximates the number of GC B cells in the 
lung 4 days later. Given that the CXCL13/CXCR5 axis is known to be important for 
promoting recruitment of GC-bound B cells to the lung after influenza (212), the 
possibility that this small subset of CXCR5+ B cells is responsible for seeding the lung 
GCs should be explored. This idea would also align with the data showing that 
preventing B cell recruitment to the lung during the second infection with FTY720 
abrogates lung GC formation a week later. Testing whether these data-driven suggestions 
hold true with further experimentation is required to conclude the studies presented here. 
Many of the results described here for BRM cells elicited by pneumococcus have 
also been explored in the context of influenza-specific lung BRM cells. Establishment of 
BRM cells after influenza infection in mice also depends on T cell interactions 




lung are also comparable after influenza and pneumococcal infections, with the caveat 
that influenza studies have described the kinetics for antigen-specific B cells, which we 
have not yet done. After an initial early B cell influx post-infection, lung B cells appear to 
take around 3 weeks to reach an equilibrium in both models (112, 139, 149). 
Additionally, CXCL13, which is known to be important for lung B cell recruitment early 
after influenza infections, also seems to correlate with recruitment of a subset of B cells 
to the lung in response to pneumococcal pneumonia. Whether CXCL13 in our model acts 
downstream of IL-17, as observed in other non-influenza settings (223), will be important 
to test given the known importance of IL-17 in anti-pneumococcal lung immunity (178). 
Other potentially important chemokine signaling axes should be investigated in our 
model, including CXCR3 and its ligands, as this receptor is commonly expressed on lung 
MBCs (112, 139).  
One obvious difference between previously described infections that elicit lung B 
cells and our model is the requirement for two infections to generate lung BRM cells 
after pneumococcal exposure. Our data indicate that a more robust CXCL13 response 
upon the second pneumococcal infection compared to the first may be part of the reason 
the first infection is not sufficient. This idea warrants a study of what cells in the lung are 
remodeled by the initial pneumococcal exposure to produce more CXCL13 on 
reinfection. An additional factor behind the two infection requirement may involve the 
presence of antigen during a critical time frame: for CD4+ T cells to transition to 
memory, encounter with cognate antigen is required around 7 days after initial antigen 




between days 3 and 5 post-infection (177), effector CD4+ T cells do not encounter 
enough presented cognate antigen to receive survival signals and transition to memory 
unless the second Sp19 infection is given. Although B cells do not follow an analogous 
effector to memory transition, they do require T cell help and perhaps cannot survive in 
the lung unless there are sufficient surviving T cells there to provide it. Experiments to 
determine whether there is a critical window in which the second Sp19 infection must be 
given to generate elevated CXCL13 and/or resident memory lymphocytes would further 
our understanding of the two infection requirement. 
A parallel idea that may explain the need for two infections in our model is that 
the severity of an infection is tied to the magnitude of the response seen in the lung. 
Evidence for this comes from a study that showed that infecting mice with a lower dose 
of influenza virus or using a less virulent strain leads to drastically lower lung GC 
responses (226). This has been confirmed in other studies; while infecting mice with the 
highly virulent PR8 strain of influenza results in around 30,000 GC B cells in the lung at 
peak (139), the less virulent X31 strain generates a peak of only around 1,000 GC B cells 
(149). The Sp19 infection given in our studies is a self-limiting infection that is fairly low 
virulence in mice. It may be that the lung resident lymphocyte responses to such a mild 
infection are minimal, but enough remodeling occurs that upon a second infection, the 
immune system is able to respond more vigorously to what it now perceives as a 
repetitive threat. 
One other area in which the pneumococcal and influenza models differ is in the 




lung GC reactions following infection resolution. In one influenza study, for example, at 
day 45 post-infection, the lungs of mice still contained around 20,000 GC B cells (139). 
This is over 100 times more than the number of GC B cells seen in our 2x pneumococcus 
recovered lungs at the 35 day time point. Given that iBALT structures readily support 
ongoing GC reactions, it will be interesting to determine whether there are more 
organized lymphocytic infiltrates in the lung one week after a second Sp19 infection. 
What is perhaps surprising is that the iBALT-free pneumococcus recovered mouse lungs 
continue to contain GC B cells at all at day 35. GCs are typically thought of as well-
defined microanatomical structures involving B cells, TFH cells, and FDCs. Although we 
have not yet formally looked for the latter two specialized cell types, CD4+ T cells are 
relatively rare within the loose B cell clusters in the lungs of pneumococcus-experienced 
mice at day 35 (Chapter 3). It will be interesting to determine whether the persistent lung 
GC B cells specifically localize near the CD4+ T cells within B cell clusters and whether 
FDCs acting as reservoirs for continued antigen presentation can also be found nearby.  
The results presented here provide initial knowledge on the cells and signals 
required for lung BRM cell establishment after resolution of pneumococcal pneumonia in 
mice. A thorough understanding of the mechanism of BRM cell establishment will be 
crucial to optimize vaccine-elicited resident memory within the lung. This is especially 
true in settings free of lung tertiary lymphoid organs such as the one presented here, as 





CHAPTER FIVE: DISCUSSION  
An integrated model of serotype-independent anti-pneumococcal immunity in mice 
In the studies presented here, we explored the phenotypes, establishment, and 
importance of lung MBC populations elicited by respiratory exposures to Streptococcus 
pneumoniae in mice. A focus of Chapter 3 was how these lung MBCs contribute to 
serotype-independent protection against pneumococcal pneumonia. These findings can 
now be integrated with previous work from our lab and others to describe a more 
complete model of the serotype-independent immune response that occurs in experienced 
mice upon Sp3 challenge (Fig. 23).  
Initial Sp19 pneumococcal exposures seed the lung with CD4+ TRM cells that 
can respond to mismatched pneumococcal serotypes and are crucial for controlling 
bacterial growth during the first 24 hours of an Sp3 challenge infection (74). The CD4+ 
TRM cells mediate this immunity through secretion of IL-17A upon reactivation, which 
stabilizes CXCL5 transcripts in lung epithelial cells. This allows for enhanced CXCL5 
secretion, driving faster neutrophil recruitment in experienced mouse lungs compared to 
lungs of naïve mice, which lack this signaling axis (178). The early time points between 0 
and 24 hours post-Sp3 are when peak cellular infiltration, vascular permeability, and 
airspace edema occur in the experienced lung (74). The increased access of blood 
components to the lung during this phase may mean that the pre-existing serotype cross-




tissue. These antibodies are predominantly of IgG isotypes, and therefore may be able to 
access the airspace via the neonatal Fc receptor, which is expressed on lung epithelial 
cells and is crucial for luminal transport of IgG (227).  
Multiple lines of evidence suggest that these pre-existing anti-pneumococcal 
antibodies play a role in protection against Sp3 challenge but are not sufficient to mediate 
bacterial clearance. First, right lobes of experienced mice, which did not receive the 
initial Sp19 exposures and do not contain resident T or B cells, are still better protected 
from an i.n. Sp3 lung challenge than right lobes of naïve mice (74, 177). This finding 
indicates that some level of systemic immunity, most likely conferred by anti-
pneumococcal antibodies, contributes to protection throughout the whole lung. However, 
experienced left lobes are even better protected from the i.n. Sp3 challenge than the 
experienced right lobes are, which shows that additional contributions from lung-
localized immune components are required for optimal anti-Sp3 immunity. Additionally, 
plasma of experienced, but not naïve, mice is able to opsonize Sp3 and prevent bacterial 
growth within 24 hours when pre-opsonized Sp3 is instilled into naïve recipient lungs. 
However, this pre-opsonization is not sufficient to mediate the bacterial clearance 
observed in immune competent experienced mice at 24 hours, again highlighting that 
plasma antibodies alone are not sufficient for full anti-Sp3 protection. A final piece of 
evidence comes from the fact that experienced mice depleted of lung MBCs while 
leaving pre-existing antibodies and TRM cells intact are better protected from Sp3 




MBCs (which play no role in 24 hour protection against Sp3), and pre-existing 
antibodies. 
As just mentioned, depletion of PD-L2+ lung MBCs from experienced mice 
renders them highly susceptible to Sp3 lung infection at 96 hours post-infection. This 
phenotype is observed despite TRM cells and pre-formed antibodies remaining intact in 
these mice. Although the mechanisms behind this loss of immunity are still under 
investigation, the timing is consistent with local reactivation of lung BRM cells into 
ASCs being required for full clearance of Sp3, which occurs in experienced mice 
between 48 and 96 hours post-infection. The lung BRM cells comprise a mix of IgM, 
IgG, and IgA isotypes, and are located within the lung parenchyma. Therefore, secreted 
antibodies would likely need to be transported into the airspace lumen to play a role in 
immunity against pneumococci there. As previously described, for secreted IgG this 
could be mediated by the neonatal Fc receptor on lung epithelial cells. If the reactivated 
IgM+ and IgA+ MBCs produce the polymeric forms of these respective antibodies, they 
could then be transported to the airspace lumen via the polymeric immunoglobulin 
receptor (pIgR). Notably, pIgR upregulation on lung epithelial cells can be mediated by 
CD4+ Th17 responses (228); this interesting potential connection between the lung T and 
B resident memory cells in our model deserves further investigation.   
Interestingly, work from another group shows that nasopharyngeal exposure to 
pneumococcal serotype 4 generated serotype cross-reactive antibodies, and i.p. transfer of 
these antibodies to naïve mice conferred 70-80% protection against subsequent i.t. 




indicates that mechanisms of serotype-independent protection may differ depending on 
serotype. Sp19 has a fairly thin capsule, while the Sp3 challenge serotype used in our 
model has a very thick, mucoid capsule that is likely very effective at preventing 
antibodies from easily accessing subcapsular antigens. This may mean that for Sp3, a 
higher antibody titer is required for effective clearance, and MBC reactivation is required 
to provide those additional antibodies.  
Many aspects of this model require further experimentation to confirm or expand 
upon. For example, a role for LLPCs within the lung has not yet been explored at all. 
Additionally, whether or not a subset of the lung BRM cell pool re-enters GC reactions 
either locally or in the lung draining lymph nodes upon reactivation is unknown, although 
these fates are certainly possible for reactivated MBCs. However, the data collected so 
far are consistent with an overall model of serotype-independent pneumococcal lung 
immunity involving early contributions of TRM cells (74, 178) and pre-existing antibody 











Figure 23. An integrated model of serotype-independent anti-pneumococcal 
immunity in mice. When Sp3 is instilled into the lungs of experienced mice that 




to two logs by 24 hours and is below the level of detection of CFU counts by 48-96 hours 
post-infection. Immune components that we have shown or that we hypothesize 
contribute to this early and late bacterial clearance are depicted. CD4+ lung TRM cells 
are reactivated to produce IL-17, which stabilizes CXCL5 transcripts in lung epithelial 
cells. CXCL5 production drives enhanced early recruitment of neutrophils into the lungs. 
Pre-existing heterotypic anti-pneumococcal IgG antibodies may also come into the 
increasingly permeable lung and be transported into the airspaces via the neonatal Fc 
receptor. Later reactivation of lung BRM cells enables them to differentiate into 
antibody-secreting cells secreting heterotypic anti-pneumococcal IgG, IgA, and IgM. 
Increased expression of the polymeric IgA receptor on lung epithelial cells may enhance 
transport of IgA and IgM into the airspaces as well. Whether reactivated lung BRM cells 
also seed new GC reactions in the lung or in draining lymph nodes is unknown. GC, 
germinal center; FcRn, neonatal Fc receptor; pIgR, polymeric Ig receptor. Created with 
Biorender.com. 
 
A preliminary model of lung MBC recruitment following pneumococcal infections 
 In Chapter 4, we explored the kinetics of MBC recruitment to the lungs after 
pneumococcal serotype Sp19 infection and what factors were required to establish this B 
cell population. One possible model of recruitment that accounts for the observations 
made is proposed below (Fig. 24). However, follow-up experiments will be required to 
formally test most aspects of the hypothesized model described here.  In this model, the 
initial Sp19 antigens are brought to the lung draining lymph node by lung DCs to initiate 
an adaptive immune response. A small amount of the B cell recruitment cytokine 
CXCL13 is produced in the lung after this initial infection, and a correspondingly small 
influx of B cells occurs, although this influx does not lead to BRM cell formation. Based 
on observations in the literature, we hypothesize that around days 5-7 after the initial 
Sp19 exposure, effector T cells generated by the first infection home back to the lung. If 
cognate antigen is present there (i.e., if a second Sp19 infection was given at day 7), these 




reside long-term in the lung. Notably, our experiments in µMT mice demonstrate that this 
TRM cell pool is established and can persist entirely independently of B cells, in contrast 
with reports of lung TRM cells dependent on B cells for maintenance in a mouse model 
of lymphocytic choriomeningitis virus (184).    
 In addition to enabling T cells to transition to a memory phenotype, the second 
Sp19 infection generates a larger CXCL13 response in the lung than the first infection 
did, which leads to a comparably larger influx of CXCR5+ B cells into the lung around a 
day later. The CXCR5+ B cells, however, are outnumbered by CXCR5- B cells coming 
into the lung at day 10 as well, many of which express a pre-GC phenotype 
(GL7+CD38hi). Based on prior literature, we hypothesize that many of these pre-GC 
phenotype B cells directly differentiate into extrafollicular MBCs of a predominantly 
IgM+ isotype. We speculate that the CXCR5+ B cell population may instead seed lung-
localized GC reactions that peak in number at day 14 and result in more lung MBC 
accumulation by predominantly class-switched, PD-L2+CD73+ B cells from day 14 
onward. The composite accumulation of these B cell populations leads to a lung B cell 
compartment at day 35 comprised of around half IgD+ B cells, 30% IgM+IgD- MBCs, 
and 20% class-switched MBCs. These B cells do not re-enter the circulation, and around 
40-60% of them express the residence marker CD69. However, the true signals required 
for these B cells to remain resident within the lung after pneumonia resolution have yet to 
be discovered. At some point during establishment, B cell interaction with CD4+ T cells 
is required for a BRM cell pool to form. However, our current results do not allow us to 




the first infection from a potential requirement for CD4+ T cell help within the lung after 
the second Sp19 infection.  
Around 2% of the lung B cells at day 35 continue to express a GC phenotype, 
despite no evidence for ongoing iBALT reactions in pneumococcus-experienced mouse 
lungs. One group has reported that proliferating B cells with a GC phenotype can exist in 
the lung outside of typical FDC-containing GC structures, although these B cells were 
found nearby CD4+ T cells with helper capabilities (229). Follow-up experiments should 
assess whether FDCs are present in pneumococcus-experienced lungs, and test whether 
the ongoing GC reactions in resting experienced lungs are important for continued 
generation of local plasma cells or MBCs.    
The persistence of a large number of IgD+IgM+ B cells in the lung at day 35 is an 
intriguing observation, as these cells would typically be classified as naïve. These IgD+ 
cells express CD69 to a comparable extent as the IgD- lung B cells, and although they do 
not express the typical mouse MBC markers PD-L2, CD73, or CD80, they are not 
depleted by anti-CD20 treatment, indicating they are also part of the resident lung B cell 
pool (these data not shown). In humans, a population of IgD+IgM+CD27+ MBCs exists 
and is not rare in peripheral blood; these cells have the same functional capacities as 
typical MBCs, as they can both differentiate rapidly into plasma cells or re-enter GCs 
(230). Recent work in a murine malaria model also identified a population of IgD+ 
MBCs, and although no functional role for these cells was described, they were found to 




explore whether IgD+PD-L2- lung B cells are also important for anti-pneumococcal lung 
immunity in some way. 
 
 
Figure 24. A preliminary model of lung MBC recruitment following two 
pneumococcal infections. Two Sp19 infections in mice are required to generate an 
appreciable lung BRM cell pool. The proposed sequence of events that lead to 
establishment of this B cell population are depicted here. We hypothesize that on initial 
Sp19 infection, lung APCs deliver pneumococcal antigens to draining lymph nodes and 
activate an adaptive immune response. A small population of CXCR5+ B cells infiltrates 
the lung, likely in response to the small amount of CXCL13 produced there. Effector 
CD4+ T cells are also recruited into the lung. Upon a second infection, these T cells are 
provided with the necessary antigen to transition into memory T cells. Additionally, 
increased lung CXCL13 production one to three days following the second infection 
drives a larger influx of CXCR5+ naïve B cells on the third day. Concurrently, a much 
larger pool of CXCR5- B cells bearing a pre-GC phenotype are recruited, and comprise a 
mix of naïve, IgM+, and class-switched cells. These pre-GC B cells have the potential to 
directly become extrafollicular MBCs. The recruited CXCR5+ B cells (and perhaps a 
subset of cells from the pre-GC phenotype pool) may seed lung-localized GCs, which 




lung class-switched MBCs starting one week after the second infection. By day 35, 
clusters of lung BRM cells are found near airways and contain rare CD4+ T cells that 
may associate with the rare remaining GC B cells in the lung. Blue B cell receptor=naïve, 
IgD+, Red B cell receptor=IgM+IgD-, Purple B cell receptor=IgM-IgD-, class-switched. 
APC, antigen-presenting cell; GC, germinal center; Teff, effector T cell; Tmem, memory 




Unresolved questions in the lung BRM cell field 
The intent of the research described here was to further our understanding of the 
contexts in which lung BRM cells occur and are important. However, many features of 
BRM cell biology still require investigation. Although the kinetics of BRM cell 
establishment appear to be consistent between studies and pathogens, one unresolved 
aspect of BRM cells is the length of time they persist in the lung. Generally, by 3 months 
after an infection, between 100 and several thousand class-switched BRM cells remain 
(112, 139, 148). BRM cells may be infrequent in the lung compared to TRM cells, but it 
has been estimated that reactivation of 10-100 MBCs is enough for production of 
biologically significant antibody titers in the serum (97); this effect would likely be 
magnified in a confined anatomical space like the lung. Therefore, detailed investigations 
of how long even small populations of antigen-specific BRM cells remain in the lung 
after infection resolution will be crucial. Whether BRM cells are maintained beyond a 6 
month time point has not yet been explored in any context. Lung CD8+ TRM cells seem 
to have short-term maintenance compared to other TRM cell populations in the body, and 
the waning of CD8+ TRM cells that occurs around 6 months post-infection corresponds 




indicates that maintenance of these CD8+ TRM cells can be extended to at least a year in 
mice if persistent antigen is provided via a vaccination approach (232). Given that MBCs 
are another cell population that contribute to heterosubtypic protection against influenza 
(233, 234) and pneumococcus (Chapter 3), whether similar dynamics are at play for these 
cells after the 6 month time point will be critical for attempts to utilize lung BRM cells in 
establishing long-term mucosal protection.   
Additional future studies should explore whether lung BRM cells are lost with 
aging, comorbidities, or upon exposure to different respiratory infections. Alternatively, 
whether the frequent exposures to respiratory pathogens like pneumococcus or influenza 
that most humans experience expand lung BRM cell populations specific to these 
microbes should be investigated as well. 
Many questions also remain regarding the reactivation of lung BRM cells. Thus 
far, antibody secretion is the only effector mechanism that has been explored, yet B cells 
can also play important roles in antigen presentation, cytokine secretion, and even 
regulation of immune responses. The enhanced expression of the co-stimulatory molecule 
CD80 on MBCs along with the co-localization of some resident memory B and T cells in 
the lung makes antigen presentation to T cells an especially interesting possibility. 
However, some MBCs can be activated independently of T cells, and whether this is true 
of lung MBCs, especially those found outside of iBALT structures, must be addressed in 
future studies. Additionally, if lung BRM cells can be activated without T cell help, it 
may make sense for a subset of these cells to be positioned within the lung airways in 




airway BRM cells could secrete antibody directly into the infected space, bypassing the 
need for epithelial transcytosis. 
MBCs and cross-reactivity 
A final aspect of MBC immunity deserving of discussion is the idea that MBCs 
represent a pool of immune memory with a diverse repertoire that can be reactivated in 
response to reinfection with a related, but not identical, pathogen variant. As alluded to in 
the introduction, MBCs exit the GC relatively early and accumulate less mutations than 
GC B cells that eventually become LLPCs (236). A consequence of this early GC 
emergence and lack of affinity maturation is that in several infection settings, MBCs 
appear to recognize variants of the initially infecting pathogen that LLPC-secreted 
antibodies cannot bind. Following West Nile virus infection in mice, LLPCs secrete 
antibody that recognizes a dominant neutralizing epitope and cannot bind a variant 
epitope on a mutated reinfecting virus (176). Antibodies from reactivated MBCs, 
however, effectively neutralize both the original and variant viruses. Another group 
showed that MBCs specific to Zika virus in human blood exhibit more cross-reactivity 
between viral types than Zika-specific serum antibodies do (237). While these studies 
provide compelling evidence that this phenomenon extends across pathogens and species, 
the majority of work on cross-reactive B cell memory has been conducted in the context 
of influenza infections. 
In mice recovered from a primary influenza infection, pre-existing antibodies 
from LLPCs are sufficient to protect against a homologous reinfection, but not against 




conserved hemagglutinin stem that were secreted by reactivated MBCs were sufficient to 
protect against heterologous challenge (234). Human blood also contains MBCs able to 
recognize hemagglutinin proteins of multiple influenza subtypes, although whether these 
MBCs are enriched in human lungs remains to be tested (233). Lungs of healthy adult 
humans and mice recovered from influenza also contain CD8+ TRM cells that can bind 
to conserved influenza antigens (135, 238). While loss of these T cells from the lung 
correlates with the loss of heterotypic influenza immunity in mice (231), these studies did 
not distinguish the protective contributions of cross-reactive memory T and B cells. It is 
likely that in a heterologous influenza infection that cannot be neutralized by pre-existing 
antibodies, both reactivated MBCs and CD8+ T cells contribute to optimal antiviral 
defense.  
A dual contribution of memory T and B cells to heterotypic immunity is also what 
we have observed in the pneumococcal infections in mice described in this thesis. Our 
data further imply that pre-existing antibodies produced by LLPCs are insufficient to 
mediate full serotype-independent protection against pneumonia in our model. One 
hypothesis that may explain this observation is that the pre-existing antibody pool is 
primarily comprised of serotype-specific antibodies, even though it does contain some 
antibodies able to bind a mismatched serotype. Based on the data described above for 
viral immunology, this would likely contrast with the lung MBCs, which may largely be 
capable of recognizing multiple pneumococcal serotypes. Formally testing whether the 
partitioning of cross-reactivity into the MBC pool holds true for pneumococcal 




an observation would have important implications for the development of a 
pneumococcal vaccine that can protect broadly against all serotypes.    
Conclusion 
In conclusion, in this study we explored the lung BRM cell populations elicited by 
respiratory exposures to S. pneumoniae. We have shown that lung BRM cells are induced 
after respiratory pneumococcal exposures in mice and are required for optimal clearance 
of a subsequent serotype-mismatched pneumococcal challenge. These results represent 
the first evidence that lung BRM cells are elicited by and contribute to immunity against 
bacterial infections. We also observed B cells with a resident memory phenotype in 
normal human lung tissue, providing preliminary evidence that lung BRM cells may be a 
common feature of healthy experienced lungs across species. Finally, we explored the 
kinetics and signals involved in lung BRM cell formation after pneumococcal 
pneumonia, and discovered that repeated antigen exposures are necessary to drive 
seeding of lung GCs and accumulation of class-switched MBCs within the lung tissue, 
potentially through a signaling axis involving CXCL13. These studies provide the 
foundation for future BRM cell studies in many infection settings and organs, and argue 
that BRM cells in the lung should be considered as potentially important correlates of 
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